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ABSTRACT 
Aims: Outcome of critically ill patients 
with acute renal failure (ARF) and 
factors related to outcome were 
evaluated.  
 
Patients and methods: A total of 1662 
patients from two intensive care units 
(ICUs) and one acute dialysis unit in 
Helsinki University Hospital were 
included in the study. The patients were 
treated in 1998-2005.  
Study I was a prospective study that 
included 668 consecutive patients treated 
in two ICUs within a period of 11 
months. The prevalence of ARF was 
calculated and classified according to 
two ARF-specific scoring methods, the 
RIFLE (Risk, Injury, Failure, Loss of 
renal function, and End-stage renal 
disease) consensus classification and the 
classification created by Bellomo et al. 
(2001). Bellomo scores classify ARF to 
three categories: acute renal injury 
(ARI), acute renal failure syndrome 
(ARFS), and severe acute renal failure 
syndrome (SARFS). 
Study II was a prospective cohort 
study evaluating human histo-
compatibility leukocyte antigen-DR 
(HLA-DR) expression and plasma levels 
of one proinflammatory (interleukin (IL) 
6) and two anti-inflammatory (IL-8 and 
IL-10) cytokines in predicting survival of 
ARF patients among 103 critically ill 
systemic inflammatory response 
syndrome (SIRS) patients treated in 
1998-1999.  
Study III was a prospective cohort 
study evaluating serum cystatin C as a 
marker of renal function in ARF and its 
power in predicting survival of ARF 
patients among 199 consecutive ICU 
patients (202 treatment episodes) over a 
period of nine months in 2003.  
Study IV was a prospective, 
randomized, and controlled cross-over 
study. Sixteen rhabdomyolysis patients 
with plasma myoglobin concentrations 
over 10 000 µg/L were allocated into two 
treatment groups. Patients were treated 
with forced alkaline diuresis (FAD) and 
hemodiafiltration (HDF). Group A 
received HDF during hours 0-4 and 
group B during hours 4-8.  
Study V was a cross-sectional cohort 
study assessing long-term survival and 
health-related quality of life (HRQoL) in 
703 patients, who had received renal 
replacement therapy (RRT) for ARF 
during 1998-2002.  
 
Main results: In Study I, Admission 
Sequential Organ Failure Assessment 
(SOFA) score and maximum RIFLE 
score for the first three days in the ICU 
were independent predictors of hospital 
mortality. The discriminative powers for 
hospital mortality of RIFLE and Bellomo 
scores as areas under curve (AUCs) were 
0.653 and 0.587, respectively. 
In Study II, ARF patients showed 
significantly lower HLA-DR expression 
and higher plasma levels of IL-6, IL-8, 
and IL-10 than nonARF patients. 
Moderate discriminative power in 
predicting survival was observed for day 
2 IL-6 and IL-10 plasma levels: AUCs 
0.703 and 0.749, respectively. 
In Study III, excellent predictive 
power in the prediction of ARF for days 
1-3 serum cystatin C was found (AUCs 
0.885, 0.893, and 0.901, respectively), 
but poor predictive power in the 
prediction of mortality. Independent 
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predictors of hospital mortality were 
diagnosis of ARF, admission APACHE 
II score, and admission plasma creatinine 
level.  
In Study IV, the decrease in plasma 
myoglobin during HDF and FAD was 
significantly greater that during FAD 
alone (28% vs. 14%). The mean 
difference in myoglobin clearances 
between the treatments was 6085µg/L. 
The mean total amount of filtrated 
myoglobin at the end of HDF was 58.4 
mg. 
In Study V, the mortality rate of ARF 
patients was 41% for 28 days, 57% for 
one year, and 70% for 5 years. Increasing 
SOFA score, increasing age, and need for 
continuous RRT were independent 
predictors of one-year mortality. The 
HRQoL, measured by the EuroQol (EQ)-
5D score, was significantly lower in the 
study population than in the age- and 
gender-matched general population (0.68 
vs. 0.86).  
 
Conclusions: Based on these results, 
neither of the ARF-specific scoring 
methods presented good discriminative 
power regarding hospital mortality. The 
maximum RIFLE score for the first three 
days in the ICU was an independent 
predictor of hospital mortality. 
As a marker of renal dysfunction, 
serum cystatin C failed to show benefit 
compared with plasma creatinine in 
detecting ARF or predicting patient 
survival. Neither cystatin C nor plasma 
concentrations of IL-6, IL-8, and IL-10, 
nor monocyte HLA-DR expression are 
clinically useful in predicting mortality in 
ARF patients.  
HDF may be used to clear myoglobin 
from plasma in rhabdomyolysis, 
especially if the alkalization of diuresis 
does not succeed. 
The long-term survival of patients 
with ARF was found to be poor. The 
HRQoL of those who survive is lower 
than that of the age- and gender-matched 
general population.  
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1. INTRODUCTION 
Acute renal failure (ARF) is a clinical 
syndrome characterized by rapidly 
decreasing glomerular filtration rate 
(GFR), which results in disturbances in 
electrolyte- and acid-base homeostasis, 
derangement of extracellular fluid 
volume, and retention of nitrogenous 
waste products, and is often associated 
with decreased urine output (Nissenson 
1998). ARF is a significant problem, 
affecting about 5% of all hospitalized 
patients (Hou et al. 1983) and about 5-
25% of patients admitted to intensive 
care units (ICUs) (de Mendonca et al. 
2000; Uchino et al. 2005). ARF is linked 
to high mortality and morbidity rates 
(Groeneveld et al. 1991). While 
comorbidities contribute to the high 
mortality rate (Biesenbach et al. 1992), 
ARF also independently increases 
morbidity and mortality (Levy et al. 
1996).  
Although ARF as a clinical syndrome 
is well known, no universally accepted 
definition exists. Commonly used 
definitions, as reviewed by Thadhani et 
al. (1996), include an increase in plasma 
creatinine of 44 µmol/L or of more than 
50% over the baseline value, a reduction 
in creatinine clearance of 50%, and a 
decrease in renal function that results in 
the need for renal replacement therapy 
(RRT). The lack of a universal definition 
for ARF complicates comparison of 
study results for prediction, treatment, 
and outcome of ARF. 
The etiology of ARF is often 
multifactorial. The most common cause 
of renal ARF is ischemia, leading to 
acute tubular necrosis (Thadhani et al. 
1996). Increasing evidence exists for the 
role of inflammatory mediators in the 
pathogenesis of ischemic ARF. Elevated 
expression of various cytokines has been 
reported in ischemic injury of the kidney 
(Goes et al. 1995; Takada et al. 1997; 
Lemay et al. 2000). Renal ischemia-
reperfusion injury has also been 
documented to augment leukocyte 
accumulation in the outer renal medulla 
(Thadhani et al. 1996) and cytokine 
release from activated leukocytes 
(Camussi et al. 1998). Other causes of 
ARF include various toxins (e.g. 
radiocontrast agents and certain 
antibiotics) and rhabdomyolysis. 
Rhabdomyolysis results in ARF for 
several reasons. Swelling of the muscles 
leads to hypovolemia and decreased renal 
perfusion. Myoglobin, leaking out of the 
damaged muscle cells, is also directly 
toxic to tubular cells (Holt et al. 2001).  
The diagnosis of ARF in clinical 
practice in the ICU is most often based 
on indirect measures of GFR, plasma 
urea and creatinine concentrations, and 
infrequently also on the clearance of 
creatinine over a 24-hour urine 
collection. Recently, a novel marker of 
renal function, cystatin C, was proposed 
to be more sensitive than plasma 
creatinine for various forms of chronic 
renal dysfunction (Newman et al. 1995; 
Plebani et al. 1998; Randers et al. 2000; 
Woitas et al. 2000). Cystatin C is 
produced by all nucleated cells (Barrett 
et al. 1984; Abrahamson et al. 1990), is 
eliminated solely by glomerular filtration 
(Tenstad et al. 1996), is freely filtered in 
the glomerulus, is neither secreted nor 
reabsorbed by renal tubules, and is 
metabolized by proximal tubular cells so 
that it does not return to blood flow in an 
intact form (Jacobsson et al. 1995). The 
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effectiveness of cystatin C in predicting 
ARF (Delanaye et al. 2004; Herget-
Rosenthal et al. 2004, 2005; Villa et al. 
2005) and as a risk factor for mortality 
(Jernberg et al. 2004; Shlipak et al. 2006) 
has been studied little. 
Hospital and ICU mortality rates of 
patients with ARF have varied from 
37%, to 88% (Groeneveld et al. 1991; 
Brivet et al. 1996; Schwilk et al. 1997). 
Due to comorbidities, mortality and 
morbidity rates may remain high after the 
initial recovery. However, few studies 
exist on mortality after one month or 
after hospital discharge; on the long term 
mortality  (Gopal et al. 1997; Korkeila et 
al. 2000; Morgera et al. 2002; Maynard 
et al. 2003), or on attainable quality of 
life after ARF (Gopal et al. 1997; 
Morgera et al. 2002; Maynard et al. 
2003). The health-related quality of life 
(HRQoL) after intensive care has been 
shown to vary according to the 
diagnostic category of the patients (Diaz-
Prieto et al. 1998; Badia et al. 2001; 
Granja et al. 2002). This has led to an 
increasing demand for studies concerning 
HRQoL in different critically ill patient 
populations (Angus et al. 2003). 
This clinical study investigates the 
value of different markers and scoring 
methods in predicting mortality of ARF 
patients.  Furthermore, these patients’ 
outcomes, as HRQoL and long-term 
survival, and the effect of intermittent 
hemodiafiltration (HDF) on myoglobin 
elimination from plasma in severe 
rhabdomyolysis are evaluated. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Definition of acute renal 
failure 
Generally, ARF is defined as an abrupt 
and sustained decline in renal function, 
which results in disturbances in 
electrolyte and acid-base homeostasis, 
derangement in extracellular fluid 
volume, and retention of nitrogenous 
waste products (Nissenson 1998). In the 
absence of specific markers for kidney 
dysfunction, this general definition has 
been applied in over 30 different ways in 
the literature thus far (Table 1). The 
degree of renal dysfunction required for a 
diagnosis of ARF has varied from a 
modest increase in serum or plasma 
creatinine concentration to severe renal 
dysfunction and the need for RRT. 
Although some definitions have been 
complex, the ones most commonly used 
have relied on the easily measurable and 
unique functions of the kidney, namely 
urine output and excretion of nitrogenous 
waste products. The clearance of 
nitrogenous waste products has usually 
been estimated indirectly by measuring 
serum or plasma creatinine concentration 
or plasma urea concentration. As 
reviewed by Thadhani et al. (1996), the 
most popular definitions of ARF are an 
increase in plasma creatinine of 0.5 
mg/dL (44 µmol/L) (Solomon et al. 
1994) or of more than 50% over the 
baseline value, a reduction in the 
creatinine clearance of 50%, and a 
decrease in renal function that results in a 
need for RRT. When urine output is 
included in the definition, the 
requirement of daily urine output has 
commonly been less than 400-500mL or 
0.5mL/kg/h.  
The need for a universally accepted 
definition of ARF has recently led to a 
proposal for a consensus definition by 
the Acute Dialysis Quality Initiative 
(ADQI) workgroup (Bellomo et al. 
2004). The workgroup proposed that the 
most useful definition of ARF is a rapid 
and sustained decrease in GFR or urine 
output, or both. They also suggested that 
an ideal definition should consider 
change from baseline and include both 
acute and chronic renal disease. The 
resulting definition, the RIFLE defi-
nition, classifies ARF into five severity 
categories (risk, injury, failure, loss of 
renal function, and end-stage renal 
disease) (Table 2). However, its valida-
tion process in large prospective studies 
is still incomplete (Bouman 2003), as is 
the recommended statistical development 
of the classification (Ruttimann 1994).
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Table 1. Definitions of acute renal failure (ARF) used in published studies.         
Reference Definition 
Hou et al. 1983 Rise in SCr ≥44 µmol/L (0.5 mg/dL) if baseline SCr ≤168 µmol/L (1.9 mg/dL) or ≥88 µmol/L (1.0 mg/dL) if baseline 
SCr 177-433 µmol/L  (2.0-4.9mg/dL) or ≥133 µmol/L (1.5 mg/dL) if baseline SCr ≥442 µmol/L (5.0 mg/dL) 
Solomon et al. 1994 Rise in SCr ≥44 µmol/L (0.5 mg/dL)  within 48 h 
Brivet et al. 1996 SCr >310 µmol/L (3.5 mg/dL) or BUN >36mmol/L (100 mg/dL) or ↑SCr/BUN >100%  in chronic renal insufficiency 
Chertow et al. 1996 Rise in SCr ≥88 µmol/L (1.0 mg/dL) in 24-48 h 
Kapoor et al. 1996 Rise in SCr ≥25% 
Levy et al. 1996 Rise in SCr ≥25% to at least 177 µmol/L (2.0 mg/dL) in two days 
Liano et al. 1996 Rise in SCr >177 µmol/L [ ≥50% if prior mild renal dysfunction (SCr ≤264 µmol/l)] or elevated SCr on admission 
Shilliday et al. 1997 SCr >180 µmol/L 
Mangano et al. 1998 Failure: need for RRT, dysfunction: SCr >177 µmol/L with an SCr increase >62 µmol/L 
Vivino et al. 1998 SCr >177 µmol/L (2 mg/dL) or an increase of over 20% from the baseline 
Behrend et al. 1999 Rise in SCr ≥80 µmol/L (0.9 mg/dL) to at least 177 µmol/L (2.0 mg/dL) (if baseline SCr <177 µmol/L) or rise in SCr 
≥133 µmol/L (1.5 mg/dL) (if baseline SCr ≥177 µmol/L) 
Conlon et al. 1999 SCr >88 µmol/L (1.0 mg/dL) postoperatively 
Hirschberg et al. 1999 SCr ≥265 µmol/L (3.0 mg/dL) with baseline SCr <159 µmol/L (1.8 mg/dL) or acute decrease in CrCl to ≤25 mL/min 
Fiaccadori et al. 2000 Rise in PCr >50% in 24-48 h or increase from baseline >1 mg/dL with known renal insufficiency 
Sirivella et al. 2000 Urine output <30 mL/h for 2-3 h and ↑SCr >44 µmol/L (0.5 mg/dL) or >50% or ↓estimated CrCl >50% 
Wang et al. 2000 Rise in SCr ≥44 µmol/L (0.5 mg/dL)  or 25% within 48 h 
Bates et al. 2001 ARF: rise in SCr ≥50% to at least 177 µmol/L (2.0 mg/dL), SARF: rise in SCr ≥100% to ≥265 µmol/L (3.0 mg/dL) 
Bellomo et al. 2001 ARI: SCr >120 µmol/L or rise >60 µmol/L and plasma urea >8 mmol/L or rise >4 mmol/L or diuresis <800 mL/24 h 
or <200 mL/6h, ARFS: SCr >240 µmol/L or rise >120 µmol/L and plasma urea >16 mmol/L or rise >8 mmol/L or 
diuresis <400 mL/24 h or <100 mL/6h, SARFS: ARI or ARFS requiring RRT 
John et al. 2001 SCr >265 µmol/L (3.0 mg/dL) and/or urine output<10 mL/h 
Mehta et al. 2001 SCr >177 µmol/L (2 mg/dL) or blood urea nitrogen ≥14.3 mmol/L (40 mg/dL)  / rise in SCr ≥88.4 µmol/L (1.0 mg/dL) 
Metnitz et al. 2002 Need for RRT 
Mehta et al. 2004 ↑SCr ≥44 µmol/L (0.5 mg/dL) if baseline SCr ≤133 µmol/L (1.5 mg/dL) or ↑SCr ≥88 µmol/L (1.0 mg/dL) if baseline 
SCr ≥133 µmol/L (1.5 mg/dL) 
Uchino et al. 2004 RRT and/or diuresis <200 mL/12 h or P-urea >30 mmol/L or BUN >31 mmol/L (86 mg/dL) or S-K >6.5 mmol/L 
Bagshaw et al. 2005 Need for RRT <48 h after ICU admission and SCr >150 µmol/L 
Fernandez et al. 2005 SCr >221µmol/L (2.5 mg/dL) 
Morelli et al. 2005 SCr >150 µmol/L 
Uehlinger et al. 2005 SCr >350 µmol/L or urine output <20mL/h 
SCr=serum creatinine concentration, PCr=plasma creatinine concentration,CrCl=creatinine clearance, 
BUN=blood urea nitrogen, P-urea=plasma urea,S-K=serum potassium, ARI=acute renal injury, 
ARFS=acute renal failure syndrome, SARFS=severe ARFS, RRT=renal replacement therapy. 
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Table 2. The RIFLE definition of acute renal failure. Adapted  from Bellomo et al.(2004).  
 GFR criteria or Urine output criteria 
Risk Increased serum creatinine x 1.5 
or decreased GFR >25% 
 <0.5 mL/kg/h x 6 h 
Injury Increased serum creatinine x 2 or 
decreased GFR >50% 
 <0.5 mL/kg/h x 12 h 
Failure Increased serum creatinine x 3 or 
decreased GFR >75% or acute 
rise in serum creatinine ≥44
µmol/L to more than 350 µmol/L 
 <0.3 mL/kg/h x 24 h  
 or anuria x 12 h  
Loss Persistent ARF, complete loss of 
kidney function >4 weeks 
 
ESRD End-Stage Renal Disease (>3 
months) 
 
GFR= glomerular filtration rate, ARF= acute renal failure. 
 
2.2. Incidence of acute renal 
failure 
Acute renal failure (ARF) is a significant 
medical problem. The overall incidence 
has varied from 8 (Korkeila et al. 2000) 
to 11 per 100 000 inhabitants/year 
(Bagshaw et al. 2005) (80-110 per 
million inhabitants/year) to 209 per 
million inhabitants over nine months 
(279 per million inhabitants/ year) (Liano 
et al. 1996). The incidence is comparable 
with the incidence of acute respiratory 
distress syndrome (ARDS), which has 
been reported as 114-198 patients per 
million inhabitants/year (Arroliga et al. 
2002). It is, however, significantly less 
than that reported for severe sepsis: 3000 
per million inhabitants/ year (Angus et al. 
2001). ARF develops in about 5 % of all 
hospitalized patients (Hou et al. 1985) 
and in 5-25% of patients admitted to 
ICUs (Groeneveld et al. 1991; Brivet et 
al. 1996; de Mendonca et al. 2000; 
Metnitz et al. 2002; Uchino et al. 2005).  
The highest incidence, approximately 
50%, has been reported in patients with 
septic shock (Rangel-Frausto et al. 1995).
 
16
2.3. Etiology of acute renal failure 
 
Table 3. Etiology of acute renal failure. 
 Etiology Reference (reviews) 
Prerenal causes  Reduced kidney perfusion 
 Volume depletion 
 Hypotension  
 Low cardiac output  
 Renal arterial vasoconstriction 
Drugs 
 NSAIDs 
 ACE inhibitors 
 Cyclosporin A 
Hou et al. 1983 
Hou et al. 1983 
Hou et al. 1983 
Hou et al. 1983 
Hou et al. 1983 
 
Markowitz et al. 2005 
Verme-Gibboney 1997  
Olyaei et al. 1999 
Postrenal causes  Obstruction of urinary outflow Thadhani et al. 1996 
Intrinsic renal 
causes 
 Acute tubular necrosis 
 Prolonged renal ischemia 
 Sepsis 
 Myoglobin (rhabdomyolysis) 
 Other nephrotoxins 
 (radiocontrast medium, 
 aminoglycosides, vancomycin, 
 fluoroquinolones, amikacin, 
 amphotericin B, aciclovir) 
Interstitial nephritis 
 Autoimmune diseases 
 Bacterial and viral infections 
 Drugs 
 (penicillins, cephalosporins, 
 azithromycin, NSAIDs) 
Glomerular nephritis 
Various mechanisms 
 (cisplatin, metothrexate, 
 cyclosporine A, gold)  
Lameire et al. 2005 
Reineck et al. 1980 (not  review) 
Harris et al. 1991 
Slater et al. 1998 
Harris et al. 1991 
 
Thadhani et al. 1996 
Thadhani et al. 1996 
Cooper et al. 1987 
 
Jennette et al. 1990 
Cooper et al. 1987 




Prerenal causes include all clinical 
conditions, that result in reduced 
perfusion in the kidneys (Hou et al. 
1983); that comprise volume depletion, 
hypotension, low cardiac output, renal 
arterial vasoconstriction, and obstruction 
of renal arteries. The reduction in GFR in 
prerenal ARF is thus at least partly 
physiologic. Drugs that can induce 
prerenal ARF include nonsteroidal anti-
inflammatory agents (NSAIDs) and 
angiotensin-converting enzyme (ACE) 
inhibitors. NSAIDs, which inhibit 
prostaglandin synthesis, reduce GFR by 
blocking the effect of locally released 
vasodilatory prostaglandins in hypo-
perfusion states, as reviewed by 
Markowitz et al. (2005). ACE inhibitors 
may induce prerenal ARF by decreasing 
the production of angiotensin II, which is 
needed in preserving glomerular 
capillary hydrostatic pressure by 
constriction of glomerular efferent 
arterioles (for review, see Verme-
Gibboney 1997). Cyclosporin A is also 
known to cause vasoconstriction of both 
afferent and efferent arterioles, leading to 
a decrease in renal perfusion and thus 




Postrenal ARF occurs when urinary 
outflow is obstructed, increasing the 
pressure in Bowman’s capsules and 
reducing the hydrostatic pressure needed 
for glomerular filtration to take place. 
Renal vasoconstriction subsequently 
occurs and GFR falls (Yucha et al. 1997). 
A requirement for the development of 
ARF is that the obstruction of urine 
outflow is below bladder level or the 
patient has only one kidney, as a second 
kidney can easily compensate for the loss 
of the first (Thadhani et al. 1996). 
 
Intrinsic renal causes 
Renal causes for ARF include all 
pathological processes in the kidney. The 
most common form of renal ARF is acute 
tubular necrosis (ATN), which is also the 
predominant form of ARF seen in septic 
patients (Harris et al. 1991). ATN can be 
classified as either intrinsic renal 
(Lameire et al. 2005) or prerenal 
(Lameire et al. 2003) since the boundary 
between prerenal ARF and ATN is fuzzy. 
Prolonged renal ischemia leads to 
increased renal damage and prerenal 
ARF develops into ATN (Reineck et al. 
1980). ATN can also be caused by 
various nephrotoxins (Harris et al. 1991), 
such as  radiocontrast agents and several 
antibacterial, -fungal, or -viral therapies, 
including aminoglycosides, vancomycin, 
fluoroquinolones, amikacin, ampho-
tericin B, and aciclovir. In addition, ATN 
is frequently caused by the toxic effects 
of myoglobin in rhabdomyolysis (Slater 
et al. 1998). 
Other intrinsic renal causes of ARF 
are more infrequent. Drugs that produce 
ARF by an intrinsic renal mechanism 
other than ATN usually do so by causing 
interstitial nephritis (Cooper et al. 1987). 
Such drugs include sulfonamide 
antibiotics, penicillins, cephalosporins, 
azithromycin, and NSAIDs.  Cisplatin, 
metothrexate, cyclosporine A, and gold 
are all also known to trigger ARF by 
various mechanisms. Interstitial nephritis 
can also be precipitated by a wide range 
of autoimmune diseases and bacterial- or 
viral infections (Thadhani et al. 1996). 
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Rapidly progressive glomerular nephritis, 
which is a source of ARF developing 
outside the hospital, is often caused by 
underlying vasculitis (Jennette et al. 
1990).  
In patients with pre-existing chronic 
renal dysfunction, the etiology of ARF is 
an insult to the kidney that is 
superimposed on the kidney dysfunction 
already present. This results in more 
severe ARF (Bouman et al. 2003) and is 
usually defined as “acute on chronic” 
renal failure (Bellomo et al. 2001; 
Bouman et al. 2003). Table 3 summa-
rizes the etiology of ARF. 
 
Risk factors 
Surprisingly few studies have focused on 
the risk factors for developing ARF. A 
large multinational study reported the 
most important risk factors present on 
hospital admission to be age over 65 
years, infection, history of chronic heart 
failure, lymphoma, leukemia, or liver 
cirrhosis (de Mendonca et al. 2000). 
Older age and liver cirrhosis were also 
found to predict development of ARF in 
a study with 257 septic/SIRS patients 
(Yegenaga et al. 2004). Another study of 
240 ARF patients found previous heart 
disease, stroke, pulmonary disease, 
diabetes mellitus, cancer, connective 
tissue disease, chronic renal dysfunction, 
and alcoholism to be predictive of ARF 
(Bagshaw et al. 2005). Large 
epidemiologic studies support the role of 
older age, diabetes mellitus, underlying 
chronic renal disease, and heart failure as 
risk factors for developing ARF (Parfrey 
et al. 1989; Mangano et al. 1998; Nash et 
al. 2002; Schmekal et al. 2004). Several 
studies on cardiac surgery patients have 
identified preoperative renal dysfunction 
and emergency operation/ heart failure 
during operation to be major risk factors 
for developing ARF postoperatively 
(Conlon et al. 1999; Stallwood et al. 
2004; Wijeysundera et al. 2006). One of 
these, a large study of 10 751 patients, 
reported the other risk factors for 
developing severe ARF and the need for 
RRT to be diabetes mellitus, previous 
cardiac surgery, and low left ventricular 
ejection fraction (Wijeysundera et al. 
2006). Other risk factors for ARF in 
cardiac surgery have been reported to be 
the use of perfusion and perfusion time, 
age, arteriovascular disease, obesity, 
male gender, mitral valve operation, need 
for a contrapulsator, and diabetes 
mellitus (Bove et al. 2004; Stallwood et 
al. 2004). In trauma patients, age, 
hemoperitoneum, hypotension and shock, 
rhabdomyolysis, need for mechanical 
ventilation, severity of trauma, and 
Glasgow Coma Score of less than 10 
have been described as risk factors for 
ARF (Vivino et al. 1998). In severe 
inflammation, such as in sepsis or SIRS, 
there is an abundance of inflammatory 
mediators in the circulation. This is a 
predisposing factor for ARF since 
inflammatory mediators play a role in the 
pathogenesis of ARF, as reviewed by 
Wan et al. (2003). The etiology of ARF 
is often multifactorial. ARF develops as a 
consequence of several simultaneous 
insults to the kidney such as septic 
inflammation and hypotension or the use 
of nephrotoxic agents. Table 4 shows 
common risk factors for ARF.
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et al. 2000 
1411 348 1 1  1 1  1 
Yegenaga et 
al. 2004 
257 28 1 1 0  1  0 
Bagshaw et 
al. 2005 
240 240  0 1 1  1 1 
Mangano et 
al. 1998 
2222 171 1  1 1  1  
Schmekal et 
al. 2004 
232 232    1  1  
Conlon et al. 
1999 
2672 211 1  1 1    
Stallwood et 
al. 2004 
2199 53 1  1   1  
Bove et al. 
2004 
5068 171 1  1 1  1  
Vivino et al. 
1998 
153 48 1    1  1 
Total  14454 1502 7 2 5 6 3 5 3
2.4. Pathogenesis of acute 
tubular necrosis 
In critically ill patients, ARF is often 
multifactorial and almost always ATN 
has a central role in the pathogenesis. In 
fact, in the literature, the terms “ARF” 
and “acute tubular necrosis” are 
frequently used interchangeably. There-
fore, this section focuses on the 
pathogenesis of acute tubular necrosis, 
which in itself is extremely complex. 
Although factors related to the 
pathogenesis of acute tubular necrosis 
have been studied in detail, controversy 
exists regarding the basic mechanisms of 
the pathogenesis. The pathogenesis 
apparently depends on the cause of acute 
tubular necrosis. Studies concerning the 
pathogenesis therefore often concentrate 
on one of the underlying causes: 
ischemia, sepsis, SIRS, or nephrotoxic 
agents.
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Ischemic acute tubular necrosis  
Ischemic acute tubular necrosis is 
basically a result from a mismatch 
between oxygen delivery and demand in 
the kidney. Ischemic injury to the kidney 
leads to adenosine triphosphate (ATP) 
depletion in renal tubular cells, impairing 
many cellular processes and inducing 
loss of cell polarity (Lieberthal et al. 
1998). Mislocalization of the ionic 
pumps also occurs, most importantly, the 
relocation of N-K ATPase to the apical 
membrane (Molitoris et al. 1992). The 
net result is cell necrosis, as reviewed by 
Thadhani et al.(1996). Several studies 
have provided evidence that in acute 
tubular necrosis a large part of cell death 
also occurs by apoptosis (Shimizu et al. 
1993; Jaffe et al. 1997; Oberbauer et al. 
1999; Ortiz et al. 2000).  
After the initial ischemic event, 
during reperfusion, a second insult to the 
kidney occurs. Studies have shown 
leukocyte accumulation in the outer renal 
medulla during reperfusion (Linas et al. 
1988; Willinger et al. 1992). Both 
neutrophils and mononuclear cells 
infiltrate the kidneys, but which ones are 
more important in ischemia-reperfusion 
injury is still being debated (Linas et al. 
1988; Klausner et al. 1989; Rabb et al. 
2000; Burne et al. 2001). Leukocyte 
adhesion is a central event in leukocyte 
recruitment to injured tissue, and the 
renal endothelium seems to play a major 
role in this. Following ischemic injury, 
the endothelial cells begin to produce 
proinflammatory cytokines and adhesive 
molecules (Adler et al. 1999). Leukocyte 
activation leads to generation of free 
radicals and cytokines (Camussi et al. 
1998). Supporting evidence exists from 
several studies that report increased 
expressions of various cytokines in 
ischemic injury in animals (Goes et al. 
1995; Takada et al. 1997; Lemay et al. 
2000) and increased IL-6 levels in renal 
injury (Smith et al. 2000). Inflammatory 
response is further augmented by 
upregulation of leukocyte-activating 
chemokines by inflammatory cytokines 
(Rahman et al. 1998; Donnahoo et al. 
1999). Oxygen free radicals have also 
been shown to be capable of activating 
T-cells (Chaudhri et al. 1986). IL-10, on 
the other hand, has been documented to 
ameliorate injury in posttransplant 
ischemic ARF (Deng et al. 2001). 
Supporting evidence comes from studies 
where eliminating IL-10 has exacerbated 
ischemic kidney injury (Hess et al. 
1997). 
 
Sepsis-induced acute tubular 
necrosis 
The pathogenesis of ATN in sepsis has 
been investigated little. The evidence of 
pathogenesis of ARF in sepsis in these 
studies has also been inconsistent. Some 
evidence points to ischemia of the kidney 
being the leading cause. Some studies 
report a reduction in total renal blood 
flow during endotoxemia (Badr et al. 
1986; Kikeri et al. 1986). Others, 
however, have found global and 
medullary renal blood flow during 
hyperdynamic sepsis to be normal or 
increased (Ravikant et al. 1977; Di 
Giantomasso et al. 2003). Whether the 
major underlying cause of ARF in sepsis 
is local vasoconstriction and ischemia or 
the inflammatory response is under 
debate (Wan et al. 2003; Lameire 2005). 
The contribution of proinflammatory 
response is favored by a study where 
tumor necrosis factor (TNF) receptor 
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knock-out mice were resistant to 
endotoxin-induced ARF (Cunningham et 
al. 2002). Another study found that 
neutralization of TNF results in a smaller 
decrease in GFR during endotoxemia in 
mice (Knotek et al. 2001). However, a 
study of rabbits with endotoxemic shock 
reported no protection from kidney injury 
with neutralization of TNF by 
monoclonal antibodies (Rodriguez-
Wilhelmi et al. 2003). Finally, apoptosis 
has been shown to be one mechanism of 
endotoxin- and cytokine-induced tubular 
cell death in ARF (Jo et al. 2002). 
 
Nephrotoxic acute tubular 
necrosis 
1. RHABDOMYOLYSIS-INDUCED ACUTE 
TUBULAR NECROSIS 
Rhabdomyolysis, the breakdown of 
skeletal muscle, can be caused by various 
factors, with direct muscle trauma, 
energy depletion, and genetic defect of 
muscle-cell metabolism being among the 
most common. However, all causes seem 
to lead to rhabdomyolysis via a common 
pathway: the release of calcium from the 
sarcolemma and cytocolic calcium 
overload (Knochel 1993), leading to 
muscle cell damage and the release of 
myocyte constituents into the circulation. 
One of the key compounds released is 
myoglobin, a heme-containing protein 
that plays a major role in development of 
rhabdomyolysis-induced ARF (Slater et 
al. 1998).  
While the precise mechanism by 
which myoglobin induces ARF is still 
unclear, three mechanisms have been 
proposed: heme protein-induced oxidant 
injury by lipid peroxidation to renal 
tubular cells, renal vasoconstriction, and 
cast formation in the renal tubuli (Holt et 
al. 2001). The presence of oxidative 
stress in the pathogenesis of ARF is 
supported by an experimental model of 
myoglobinuric ARF in which treatment 
with antioxidants reduced morphological 
changes in renal cells (Chander et al. 
2003) The lipid peroxidation has been 
suggested to occur either by release of 
free ferrous (Fe2+) iron, resulting in 
generation of hydroxyl radicals via the 
Fenton reaction, or by redox cycling of 
ferric (Fe3+) myoglobin to lipid 
peroxidation, inducing ferryl ([Fe=O]2+)
myoglobin (Hogg et al. 1994) Renal 
vasoconstriction is said to result from the 
formation of potent renal vaso-
constrictors, F2-isoprostanes, as a by-
product of lipid peroxidation (Morrow et 
al. 1990; Takahashi et al. 1992; Moore et 
al. 1998), or from heme-protein induced 
nitric oxide (NO) scavenging (Sharma et 
al. 1987; Neto et al. 1988; Furchgott et 
al. 1991; Gorbunov et al. 1995), which 
inhibits NO-induced vasodilatation. Cast 
formation in the renal tubuli occurs when 
the heme protein concentration in renal 
tubuli increases in rhabdomyolysis. Cast 
formation is further increased when urine 
pH decreases, as the heme protein 
aggregates with Tamm-Horsfall proteins 
in renal tubular cells, as reviewed by 
Zager (1996). In addition, cast formation 
increases the concentration of myoglobin 
in renal tubuli. Finally, hypovolemia-
induced reduction in renal blood flow has 
a central role in the pathogenesis of 
rhabdomyolysis-induced acute tubular 
necrosis. Following muscle injury, a 
marked decrease can occur in blood 
volume, as fluid is taken up into the 
damaged muscle cell (Slater et al. 1998). 
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2. CONTRAST MEDIA-INDUCED ACUTE 
TUBULAR NECROSIS 
The pathogenesis of contrast media-
induced acute tubular necrosis is in many 
ways similar to the pathogenesis of 
rhabdomyolysis-induced acute tubular 
necrosis. Evidence has emerged for a 
direct toxic effect of contrast media on 
renal tubular cells (Battenfeld et al. 1991; 
Ueda et al. 1993; Katholi et al. 1998; 
Hizoh et al. 2002). Furthermore, contrast 
media induce ARF nonspecifically by 
hyperosmolality, which has been found 
to augment renal vasoconstriction (Reed 
et al. 1983) and thus ischemia to the 
kidney. In addition, GFR is reduced by 
an increase in intratubular hydrostatic 
pressure created by the high osmolarity 
of urine (Katzberg 1997). A meta-
analysis of randomized trials revealed 
that the risk for nephropathy was lower 
with hypo-osmolar than with 
hyperosmolar contrast media (Barrett et 
al. 1993). Risk seemed to be highest 
when hyperosmolar contrast media was 
used in patients with pre-existing renal 
disease. Finally, several studies have 
demonstrated an association between a 
high dose of contrast medium and greater 
risk for ARF (McCullough et al. 1997; 
Freeman et al. 2002; Rihal et al. 2002). 
 
2.5. Diagnosis of acute renal 
failure 
Diagnostic markers 
1. INULIN CLEARANCE - GOLD STANDARD 
In renal failure, inulin clearance is 
regarded as the gold standard, i.e. most 
accurate diagnostic technique available, 
for determining GFR (Perrone 1992). 
Drawbacks with the inulin clearance 
method are that it requires an intravenous 
infusion, is laborious, and is expensive. 
 
2. ISOTOPE AND IOHEXOL CLEARANCES 
Plasma clearances of various isotopes 
(51Cr-EDTA, 99mTc-DTPA, 125I-iothala-
mate) (Dubovsky et al. 1982; Perrone et 
al. 1990) and iohexol (Brown et al. 1991) 
have also performed well as markers of 
renal function. Only minimal differences 
have been observed between inulin 
clearance and isotope (Rehling et al. 
1984; Perrone et al. 1990) or iohexol 
(Brown et al. 1991) clearance. These 
methods are, however, too complicated 
for clinical use. 
 
3. SERUM / PLASMA CREATININE AND 
CREATININE CLEARANCE 
Creatinine measurement from serum or 
plasma is the most commonly used 
marker of renal function. Serum and 
plasma concentrations of creatinine have 
been shown to correspond to each other 
(Mazzachi 2000). Creatinine is an 
endogenous marker generated in muscle 
from creatine and creatine phosphate 
(Wyss et al. 2000). Creatinine fulfills a 
central requirement for an endogenous 
marker of GFR; it is freely filtered in the 
glomerulus. However, it is also secreted 
in the tubulus in substantial amounts. The 
tubular secretion is proportional to the 
plasma creatinine concentration, leading 
to an overestimation of GFR. A decrease 
of at least 50% in GFR is usually needed 
for serum/plasma creatinine concen-
tration to increase markedly (Renkin et 
al. 1974). The accuracy of serum/plasma 
creatinine determination is also 
influenced by its generation being 
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proportional to muscle mass (Perrone et 
al. 1992). Finally, age, gender, and diet 
have been shown to affect serum/plasma 
creatinine concentration (Jacobsen et al. 
1980; James et al. 1984).  
Creatinine clearance typically 
provides an estimation of the 24-hour 
excretion of creatinine in urine. 
However, it overestimates GFR due to 
tubular secretion of creatinine, and many 
studies have found high day-to-day 
variation (Paterson 1967; Guillausseau et 
al. 1988). Furthermore, a review on the 
subject concluded that creatinine 
clearance-based estimates of GFR show a 
worse correlation with actual GFR than 
estimates based on plasma creatinine 
(Walser 1998).  
 
4. PLASMA UREA /BLOOD UREA 
NITROGEN 
Urea nitrogen is an end-product of 
protein metabolism in the liver. It is 
freely filtered in the glomerulus. 
However, it undergoes renal tubular 
reabsorption and is therefore unreliable 
as an estimate of GFR. Moreover, the 
production rate of urea nitrogen is not 
stable; it depends on liver function,  
protein intake, and catabolism (Reynolds 
1992; Waterlow 1994). Catabolism-
inducing drugs, such as corticosteroids, 
increase plasma urea/blood urea nitrogen 
concentrations via increased protein 
degradation (Wray et al. 2002). Plasma 
urea/blood urea nitrogen concentration 
has also been shown to increase in 
patients with gastrointestinal bleeding 
(Stellato et al. 1980). This is thought to 
result from the degradation of blood in 
the gastrointestinal tract and is more 
profound in upper gastrointestinal 
hemorrhage (Snook et al. 1986; Ernst et 
al. 1999). 
 
5. SERUM CYSTATIN C
Cystatin C, a member of the cystatin 
superfamily,  is an inhibitor of cysteine  
proteases (Barrett et al. 1984). It is a 
novel marker of renal function, and, 
theoretically, is an ideal endogenous 
marker of renal function. It meets all 
requirements for such a marker; it is 
produced at a constant rate by all 
nucleated cells (Barrett et al. 1984; 
Abrahamson et al. 1990), eliminated 
solely by glomerular filtration (Tenstad 
et al. 1996), freely filtered in the 
glomerulus due to its low molecular 
weight, and is neither secreted nor 
reabsorbed by renal tubules. Cystatin C is 
metabolized by proximal tubular cells so 
that it does not return to blood flow in an 
intact form (Jacobsson et al. 1995).  
A few limitations for the use of 
cystatin C in clinical practice exist. It has 
previously been described as being 
independent of gender (Finney et al. 
2000; Johnston et al. 2004) and muscle 
mass (Vinge et al. 1999).  However, one 
study reported that increasing body mass 
index and cigarette smoking were 
associated with a higher serum cystatin C 
concentration (Galteau et al. 2001). 
These results were supported by another 
study, in which increasing age, weight, 
increasing height, and C-reactive protein 
(CRP) as well as male gender, and 
smoking were all independently 
associated with higher serum cystatin C 
levels (Knight et al. 2004). In the latter 
study, the results could not be solely 
explained by the variables’ effects on 
renal function, as the results were 
adjusted for GFR. The reference range 
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for cystatin C is stable through most of 
adulthood, but after the age of 50 years 
cystatin C concentration tends to increase 
with decreasing GFR (Finney et al. 2000; 
Randers et al. 2000; Johnston et al. 
2004). In children older than one year, 
cystatin C has been shown to be 
independent of age (Bokenkamp et al. 
1998; Finney et al. 2000).  Large doses 
of glucocorticoids have been described to 
increase serum cystatin C concentration 
(Bjarnadottir et al. 1995; Risch et al. 
2001). Also, thyroid function affects 
serum cystatin C concentrations (Fricker 
et al. 1944; den Hollander et al. 2003; 
Wiesli et al. 2003). Moderate removal of 
cystatin C from plasma during 
hemodialysis has been demonstrated, but 
the precise amount remains obscure 
(Thysell et al. 1988; Kabanda et al. 1994; 
Tian et al. 1997; Campo et al. 2004). 
Based on evidence from several 
studies, cystatin C seems to be a superior 
marker for detection of early renal 
dysfunction in chronic renal impairment 
(Plebani et al. 1998; Randers et al. 1998, 
2000; Woitas et al. 2000; Mussap et al. 
2002; Christensson et al. 2004; Grubb et 
al. 2005). It has particularly been 
evaluated in subject groups such as 
children (Willems et al. 2003; Grubb et 
al. 2005), the elderly (Van Den 
Noortgate et al. 2002), and patients with 
decreased muscle mass (Thomassen et al. 
2002), where estimating GFR by 
creatinine-based methods is known to 
yield unreliable results. A meta-analysis 
of 20 studies concluded that cystatin C 
appears to be a more accurate marker 
than creatinine (Laterza et al. 2002). 
However, several studies have provided 
contradictory evidence, finding cystatin 
C to not be superior to other estimates of 
GFR (Risch et al. 2001; Van Den 
Noortgate et al. 2002; Willems et al. 
2003; Gabutti et al. 2004). Studies on 
cystatin C in ARF and in critical illness 
are sparse. One recent study in critically 
ill patients reported cystatin C to increase 
faster than creatinine in ARF patients 
(Herget-Rosenthal et al. 2004). The study 
also reported thyroid function and use of 
glucocorticoids to not have an effect on 
cystatin C concentration. Another study 
found cystatin C to have a high 
correlation with creatinine clearance in 
critically ill patients (Villa et al. 2005). 
Good predictive ability concerning small 
decreases in GFR in critically ill patients 
has been noted in two studies (Delanaye 
et al. 2004; Villa et al. 2005). Another 
study reported a more rapid increase in 
serum cystatin C than in serum creatinine 
after nephrectomy (Herget-Rosenthal et 
al. 2005). A small study on 29 septic 
patients observed no correlation between 
cystatin C and the occurrence of ARF 
(Mazul-Sunko et al. 2004).  
Research of cystatin C in outcome 
prediction is sparse. A recent study 
reported serum cystatin C concentration 
to independently predict long-term 
mortality in hospitalized patients with 
acute coronary syndrome (Jernberg et al. 
2004). These authors also reported the 
relative risk for death to increase with 
increasing serum cystatin C concen-
tration. Another study found increasing 
serum cystatin C concentration to be 
associated with increasing mortality in a 
cohort of well-functioning elderly 
persons (Shlipak et al. 2006). Finally, 
one small study on critically ill patients 
treated with RRT noted higher serum 
cystatin C concentrations in nonsurvivors 
than in survivors (Balik et al. 2005). 
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Models for estimation of 
glomerular filtration rate 
Several formulas for the estimation of 
GFR exist (Cockcroft et al. 1976; 
Schwartz et al. 1987; Levey et al. 1999). 
Two of these, the Cockcroft-Gault 
formula (Cockcroft et al. 1976) and the 
“Modification of Diet in Renal Disease” 
(MDRD) formula (Levey et al. 1999), are 
typically used in adults. The older 
Cockcroft-Gault formula is used more 
extensively. For men, GFR 
(mL/min/1.73m2) can be calculated as 
follows:  
 
(140 - age) x weight 
72 x serum creatinine (mg/dL) 
For women, the equation needs to be 
multiplied by 0.85. The MDRD formula 
can be calculated as follows: 
 
GFR (mL/min/1.73m2) = exp(5.228 - 
1.154 x ln(SCr (mg/dL)) - 0.203 x 
ln(age) - (0.299 if female) + (0.192 if 
African-American)).  
 
For both formulas, conversion of serum 
creatinine concentrations from µmol/L to 
mg/dL has to be made by dividing the 
values by 88.4. The MDRD formula 
formula takes into account the effects of 
age, gender, and race and has recently 
been recommended by the ADQI 
workgroup (Bellomo et al. 2004). In the 
original study by Levey et al. (1999) the 
MDRD formula performed better as an 
estimate of GFR than the Cockcroft-
Gault formula.  The debate of whether 
the Cockcroft-Gault formula or the 
MDRD formula gives more accurate 
estimations of GFR continues today 
(Vervoort et al. 2002; Pierrat et al. 2003; 
Rigalleau et al. 2005; Poggio et al. 2006).  
 
Severity scoring 
1. GENERAL SEVERITY-OF-ILLNESS 
SCORING METHODS 
The Acute Physiology and Chronic 
Health Evaluation (APACHE) II score is 
a measure of the general severity of 
illness, originally developed for 
calculating risk for death in critically ill 
patients (Knaus et al. 1985). The score is 
determined using the patient’s age, 
premorbid chronic health, and twelve 
physiologic variables representing 
current severity of illness.  Sequential 
Organ Failure Assessment (SOFA) is 
aimed at determining the severity of 
organ dysfunctions (Vincent et al. 1996). 
Subscores for six organ systems are 
determined, and the score is calculated 
by addition of these subscores. SOFA 
score originally was not created for 
outcome prediction, but it has performed 
well (de Mendonca et al. 2000; Janssens 
et al. 2000; Mehta et al. 2002; Peres Bota 
et al. 2002; Carbonell et al. 2004). 
 
2. ARF-SPECIFIC SEVERITY- OF-ILLNESS 
SCORING METHODS 
ARF-specific severity-of-illness scoring 
methods can be divided into two groups; 
those that focus on determining the 
severity of ARF (Vincent et al. 1996; 
Bellomo et al. 2001; Bellomo et al. 2004) 
and those that determine the general 
severity of illness in ARF patients (Liano 
et al. 1993; Paganini et al. 1996; Chertow 
et al. 1998; Lins et al. 2000; Mehta et al. 
2002). The number of scoring methods of 
the first group is limited. The SOFA 
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score can be classified in the first group, 
as it includes a specific subscore for renal 
dysfunction. The SOFA subscore for 
renal organ dysfunction is determined by 
plasma creatinine concentration and 
urine output as follows: score 0: plasma 
creatinine 110 µmol/L (nonARF), score 
1: plasma creatinine 110-170 µmol/L, 
score 2: plasma creatinine 171-299 
µmol/L, score 3: plasma creatinine 300-
440 µmol/L or urine output 201-500 mL/ 
24 h, and score 4: plasma creatinine >440 
µmol/L or urine output <200 mL/ 24 h 
(Vincent et al. 1996). Besides the renal 
SOFA score, only two other ARF-
specific scoring methods that focus on 
determining the severity of renal 
dysfunction exist: the RIFLE classi-
fication (Bellomo et al. 2004) (Table 2) 
and the Bellomo classification (Bellomo 
et al. 2001) (Table 1). These scoring 
methods deal with ARF as a continuum 
and distinguish mild, moderate, and 
severe forms from one another. They also 
contain specific criteria for “acute on 
chronic” renal failure.  
The second group of ARF-specific 
scoring grades the general severity of 
illness in ARF patients. The main focus 
is on prediction of survival. The scores 
calculate a probability or odds ratio for 
death using mainly the patient’s age and 
gender and the presence of other organ 
failures (Liano et al. 1993; Paganini et al. 
1996; Chertow et al. 1998; Lins et al. 
2000; Mehta et al. 2002).  
 
2.6. Prevention and treatment 
of acute renal failure 
Several therapeutic approaches have 
been suggested for prevention of ARF. 
However, only a few of them have been 
verified as valid. The cornerstones for 
prevention of ARF include elimination of 
nephrotoxic medication (Lameire et al. 
2003), hydration with saline (Solomon et 
al. 1994; Shimazu et al. 1997), and 
maintenance of adequate perfusion 
pressure (Bellomo et al. 2005). In many 
cases, decreasing the dosage of a 
nephrotoxic agent helps. The risk for 
ARF has been shown to decrease with a 
once-daily dose versus multiple doses of 
aminoglycosides (Prins et al. 1993). In 
addition, lowering the dose of 
radiocontrast agents decreases mortality 
(McCullough et al. 1997). 
 
Hydration 
Saline hydration has been proven 
effective in reducing the risk of 
radiocontrast-induced nephropathy 
(McCullough et al. 1997; Taylor et al. 
1998; Stevens et al. 1999; Mueller et al. 
2002; Merten et al. 2004). In patients at 
risk for contrast-media nephropathy, no 
benefit over hydration with saline alone 
has been found with mannitol, dopamine, 
or furosemide (Solomon et al. 1994; 
Stevens et al. 1999). In rhabdomyolysis, 
aggressive fluid therapy decreases the 
risk of ARF (Shimazu et al. 1997; Gunal 
et al. 2004). Whether crystalloids or 
colloids are ideal resuscitation fluids in 
critical illness is under debate 
(Schierhout et al. 1998; Choi et al. 1999; 
Waikar et al. 2000). Some evidence has 
emerged suggesting that hydroxyethyl 
starch (HES) has side-effects on renal 
function. It promotes osmotic nephrosis 
presenting as proximal tubular swelling 
and vacuolization (Legendre et al. 1993). 
One study compared the effects of HES 
with gelatin infusions in brain-dead 
donors and found the incidence of ARF 
after transplantation to be significantly 
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higher in the HES group than in the 
gelatin group (Cittanova et al. 1996). 
HES and gelatine were also compared in 
a multicenter trial in patients with severe 
sepsis, where administration of HES was 
revealed to be an independent risk factor 
for ARF (Schortgen et al. 2001). Hence, 
gelatine is generally recommended over 




Loop diuretics have been used widely to 
promote diuresis in oliguric ARF. 
However, several studies have provided 
evidence of their lack of effectiveness in 
preventing ARF (Lassnigg et al. 2000; 
Uchino et al. 2004). Some studies have 
suggested that use of loop diuretics is 
associated with increased mortality in 
ARF patients (Mehta et al. 2002), but a 
large multicenter study did not confirm 
these findings (Uchino et al. 2004). A 
recent meta-analysis also could not 
demonstrate increased mortality with the 
use of furosemide in ARF, nor did it, 
however, find furosemide useful in ARF 
(Ho et al. 2006). 
 
Urine alkalization 
Urine alkalization with sodium 
bicarbonate infusion is commonly used 
in rhabdomyolysis to prevent ARF. To 
what extent urine alkalization affects 
myoglobin clearance and metabolic rate 
remains unclear since controversy exists 
regarding the metabolism of myoglobin. 
However, in acidic surroundings, 
metmyoglobin has been shown to induce 
vasoconstriction (Heyman et al. 1997), 
and hemoglobin accumulation in the 
kidney increased in an animal model 
(Zager et al. 1989). It has also been 
suggested that the alkalization of diuresis 
prevents ARF by reducing the redox 
cycling of the ferric - ferryl myoglobin 
(Moore et al. 1998), thus preventing lipid 
peroxidation, the death of renal tubular 
cells, and renal vasoconstriction. 
However, some studies have 
demonstrated that GFR has little effect 
on myoglobin clearance rate in 
rhabdomyolysis, suggesting that myo-
globin metabolism is mainly extrarenal 
(Wakabayashi et al. 1994; Lappalainen et 
al. 2002).  
 
N-acetylcysteine 
N-acetylcysteine (NAC) in the 
prevention of ARF has been investigated 
with controversial results. Some studies 
have yielded positive results in 
prevention of radiocontrast-induced ARF  
(Tepel et al. 2000; Kay et al. 2003), 
whereas others have found it to possess 
no beneficial effects (Briguori et al. 
2002). One study found NAC to reduce 
the occurrence of ARF after contrast 
media, but did not find any benefits in 
long-term outcome (Miner et al. 2004). 
Moreover,  a study on the effect of NAC 
in preventing of ARF after coronary 
artery bypass graft surgery yielded 
negative results (Burns et al. 2005). The 
mechanism by which NAC prevents ARF 
is suggested to be suppression of oxidant 
stress (Drager et al. 2004). Some 
evidence exists that NAC might reduce 
serum creatinine concentration by 
extrarenal mechanisms, and the decrease 
seen in serum creatinine concentration 
might therefore not reflect an actual 
increase in GFR (Hoffmann et al. 2004). 
However, the side-effects of oral NAC 
are minimal, and most meta-analyses 
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recommend its use in patients with 
chronic renal dysfunction (Birck et al. 
2003; Isenbarger et al. 2003; Alonso et 
al. 2004; Liu et al. 2005). A recent 
systematic review, including 15 studies 
and 1776 patients, reported a decrease in 
serum creatinine concentrations after 
NAC, but did not find any clinically 
significant benefits in prediction of ARF 
(Pannu et al. 2004). These authors also 
reported significant heterogeneity 
between trial results. Finally, two recent 
meta-analyses found the heterogeneity of 
clinical studies to be too great for any 
definitive conclusions (Kshirsagar et al. 
2004; Zagler et al. 2006). Kshirsagar et 
al. (2004) conducted a meta-analysis 
with 16 prospective clinical trials and 
1538 patients and noted that the 
heterogeneity of current clinical studies 
prevents any meaningful conclusions 
being drawn. The meta-analysis by 
Zagler et al. (2006) included 13 trials and 
1892 patients with chronic renal 
insufficiency undergoing coronary 
angiography. In that meta-analysis, the 
risk reduction for ARF was 0.68, but the 
upper limit of the 95% CI for the risk 
reduction exceeded 1.0 in the NAC 
group. Evidence exists that the effect of 
NAC on serum creatinine concentration 
might result for reasons other than 
improving GFR (Genet et al. 2000; 
Hoffmann et al. 2004). Therefore, the 
effect of NAC on firm clinical end-
points, such as occurrence of ARF or 
mortality, is difficult to interpret from 




Traditionally, low-dose dopamine 
infusion has been the method of choice 
for renal protection. Several studies have 
been published on prevention of ARF 
and on treatment of early ARF. The 
majority of these studies have not 
provided evidence for renal protective 
effects of low-dose dopamine (Gare et al. 
1682; Chertow et al. 1996; Palsson et al. 
1997; Bellomo et al. 2000). The results 
were confirmed by a systematic review 
(Marik 2002) and two meta-analyses. In 
the meta-analysis by Kellum et al. 
(2001), dopamine did not prevent 
mortality, onset of acute renal failure, or 
need for dialysis. Another meta-analysis 
by Friedrich et al. (2005) with 61 trials 
and 3359 patients found no effect of low-
dose dopamine on mortality, need for 
RRT, or adverse events. Low-dose 
dopamine therapy has been associated 
with such side-effects as impaired 
hemodynamics (Leier et al. 1978; 
Stephan et al. 1990; Chiolero et al. 1991; 
Duke et al. 1994), impaired 
gastrointestinal motility (Tarling et al. 
1997; Dive et al. 2000), increased gut 
ischemia despite an increase in 
splanchnic perfusion (Giraud et al. 1984; 
Segal et al. 1992; Marik et al. 1994), 
impaired pituitary gland function (Van 
den Berghe et al. 1994), and suppression 
of respiratory drive (Welsh et al. 1978; 
Nishino et al. 1981; Olson et al. 1982; 
Ward et al. 1983; Shoemaker et al. 1989; 
van de Borne et al. 1998). A wide 
consensus therefore exists regarding the 





Fenoldopam is a selective dopamine α-1 
agonist (Singer et al. 1998), that 
decreases renal vascular resistance and 
increases renal blood flow and GFR 
(Bakris et al. 1999). Animal studies have 
shown that fenoldopam affects renal 
hemodynamics and may improve renal 
perfusion (Bakris et al. 1999). Similar 
results have been demonstrated in 
nonrandomized clinical studies 
(Madyoon et al. 2001). However, in 
randomized placebo-controlled double-
blind trials, those results could not be 
verified (Stone et al. 2003; Bove et al. 
2005). A recent study on ICU patients 
found fenoldopam ineffective in reducing 
mortality or the need for RRT (Tumlin et 
al. 2005). Another study of 315 patients 
with chronic renal dysfunction who 
received radiocontrast agents revealed no 
benefit on mortality (Stone et al. 2003). 
 
3. ATRIAL NATRIURETIC PEPTIDE 
Atrial natriuretic peptide (ANP) is 
secreted by cardiac atria. In animal 
studies, it has been shown to promote 
preglomerular arteriolar dilatation and 
postglomerular arteriolar constriction 
(Shaw et al. 1987). One human study 
reported improved GFR and reduced 
need for RRT, but no effect on mortality 
(Rahman et al. 1994). Several studies 
about ANP have failed to show improved 
survival of ARF patients (Kurnik et al. 
1998; Meyer et al. 1999). On the other 
hand, an 11% (95% CI 1-21%) decrease 
in dialysis-free survival has been 
reported with ANP in a placebo-
controlled multicenter study of 378 
critically ill patients with nonoliguric 
ARF (Allgren et al. 1997). In this study, 
worsening outcome was thought to be 
due to systemic hypotension induced by 
ANP. The authors also reported an 18% 
(95% CI 5-32%) improved dialysis-free 
survival in oliguric ARF patients, but 
these findings could not be verified in 
another study (Lewis et al. 2000). 
 
Other agents 
Several studies have shown that 
hydration with mannitol does not prevent 
ARF (Gubern et al. 1988; Ip-Yam et al. 
1994; Solomon et al. 1994; Stevens et al. 
1999). Mannitol increases oxygen 
consumption in the renal outer medulla, 
and it has been proposed to actually be 
harmful in ARF (Solomon et al. 1994). A 
recent study in trauma patients with 
rhabdomyolysis found no decrease in the 
need for RRT or mortality in patients 
who had received mannitol with sodium 
bicarbonate versus in those who had not 
(Brown et al. 2004). Controversial results 
also exist. Administering mannitol, 
furosemide, and dopamine simul-
taneously has been reported to decrease 
the need for RRT markedly in 
postoperative ARF patients with 
adequate cardiac output (Sirivella et al. 
2000).  
Theophylline and aminophylline, 
competitive adenosine antagonists, have 
been proposed to reduce the radiocontrast 
agent-induced ARF. A recent meta-
analysis by Ix et al. (2004) with seven 
randomized controlled trials and 480 
patients, found the increase in serum 
creatinine concentration after contrast 
medium to be 11.5 µmol/L less in 
patients who had received either 
theophylline or aminophylline than in 
patients who had not (Ix et al. 2004).  
However, they concluded that the clinical 
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significance of this small difference is 
unclear.  
Calcium channel blockers have been 
suggested to prevent reperfusion injury 
and be beneficial in preventing ATN. 
Randomized studies on calcium channel 
blockers in post-transplant ATN were 
recently systematically analyzed by 
Shilliday et al. (2005). They found 
calcium channel blockers to reduce the 
incidence of postoperative ATN if 
administered during the kidney transplant 
operation. However, they observed no 
significant difference in mortality and 
concluded that the number of 
standardized studies on this subject is too 
small for definitive conclusions. 
Other substances that have been 
investigated are numerous. They include 
growth factors (Hirschberg et al. 1999; 
Hladunewich et al. 2003; Nagano et al. 
2004), ascorbic acid (Norio et al. 2003; 
Klouche et al. 2004), magnesium (Wong 
et al. 1989; Dowd et al. 1995; Bäcklund 
et al. 2000), and allopurinol (Alatas et al. 
1996; Kim et al. 1999; Willgoss et al. 
2003). 
 
Renal replacement therapy 
Common indications for acute RRT 
include volume overload, hyper-
potassemia, metabolic acidosis, and 
uremia (Lameire et al. 2005). In critically 
ill adults, the dialysis modality chosen is 
usually either intermittent or continuous 
venovenous RRT. The effect of dialysis 
modality on mortality in critically ill 
patients has been investigated widely. No 
clear difference in mortality between 
patients treated with intermittent or 
continuous modalities has been found 
(John et al. 2001; Mehta et al. 2001; 
Augustine et al. 2004; Uehlinger et al. 
2005). One of the studies reported a 
higher mortality rate for continuous renal 
replacement therapy (CRRT) than for 
intermittent therapy. However, after 
adjusting for severity of illness, no 
differences were present between the 
groups (Mehta et al. 2001). A meta-
analysis with a total of 1400 patients 
found no mortality difference between 
continuous and intermittent RRT with a 
relative risk of 0.93 (95% CI 0.79-1.09) 
(Kellum et al. 2002). However, they also 
reported great heterogeneity between 
studies. After adjusting for severity of 
illness and study quality, a decrease in 
mortality was observed for the CRRT 
group (Kellum et al. 2002). A more 
recent large multicenter trial also could 
not demonstrate a difference in 60-day 
mortality in multiorgan dysfunction 
patients treated with intermittent 
hemodialysis versus continuous veno-
venous hemodiafiltration (Vinsonneau et 
al. 2006). However, evidence suggesting 
more favorable effects on hemodynamics 
with CCRT has been provided (John et 
al. 2001). In addition, early admi-
nistration and a bigger dose of RRT have 
been proposed to reduce mortality. 
Random assignment of patients into 
groups receiving different doses of 
continuous venovenous hemofiltration 
(CVVH) demonstrated improved survival 
in patients in the higher-dose group 
(Ronco et al. 2000). Similar results were 
reported in a study with intermittent 
hemodialysis where patients were 
assigned to receive daily or alternate-day 
treatments (Schiffl et al. 2002). 
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2.7. Outcome of acute renal 
failure 
Mortality  
The mortality rate in ARF varies. 
Mortality rates in ICU have ranged 
between 43% and 63% (Groeneveld et al. 
1991; de Mendonca et al. 2000) and for 
the hospital mortality overall between 
58% and 74% (Brivet et al. 1996; Neveu 
et al. 1996; Uchino et al. 2005). The 
great variation in mortality rates reflects 
the correlation between the degree of 
renal dysfunction required for the 
definition of ARF and the corresponding 
mortality (Kellum et al. 2002). A recent 
review evaluating 80 clinical studies on 
ARF concluded that the short-term 
mortality rate is around 50% (Ympa et al. 
2005). Also, a large multi-national, 
multicenter study with 29 269 critically 
ill patients reported a hospital mortality 
rate of 60% among ARF patients 
(Uchino et al. 2005). 
Comorbidities affect mortality and 
morbidity, which remain high after initial 
recovery (Gopal et al. 1997; Korkeila et 
al. 2000; Morgera et al. 2002; Maynard 
et al. 2003). Substantial long-term 
sequelae after critical illness have been 
described (Niskanen et al. 1996; Hurel et 
al. 1997; Ridley et al. 1997; Kaarlola et 
al. 2003). A recent study on 
cardiopulmonary bypass patients 
requiring RRT for ARF postoperatively 
found their long-term outcome to be 
relatively good: 1- and 5-year survival 
rates were 53% and 52%, respectively 
(Luckraz et al. 2005). Moreover, only 2% 
of patients required long-term renal 
support. Similar results were reported in 
a study on ARF patients treated with 
RRT (Bell et al. 2005), with the overall 
60-day mortality rate being 55%, after 
which mortality decreased rapidly; the 
overall 6-month mortality rate was 60%.  
 
Quality of life 
Quality of life has been evaluated by 
measuring patients’ health-related quality 
of life (HRQoL), which covers three 
main aspects; the patient’s physical, 
psychological, and social status (Guyatt 
et al. 1993; Angus et al. 2003; Wu et al. 
2004). In heterogeneous ICU patient 
populations, the most decreased 
dimension of HRQoL varies. Some 
studies describe the worst results in the 
‘physical’ dimension (Tian et al. 1995), 
and others in the ‘emotional’ (Granja et 
al. 2002; Kaarlola et al. 2003) or ‘usual 
activities’ (Konopad et al. 1995; Metnitz 
et al. 2002) dimension. A study 
comparing the HRQoL of former ICU 
patients with a community sample found 
that the former ICU patients reported 
worse HRQoL in 6 of the 8 scales 
(Flaatten et al. 2001). As diagnosis has 
been shown to affect HRQoL after 
intensive care (Hurel et al. 1997; Ridley 
et al. 1997; Diaz-Prieto et al. 1998; Badia 
et al. 2001; Granja et al. 2002), an 
increasing demand for studies on HRQoL 
in different critically ill patient 
populations has arisen (Angus et al. 
2003). Studies on HRQoL after ARF are 
sparse (Gopal et al. 1997; Korkeila et al. 
2000; Morgera et al. 2002), as recently 
reviewed by Radhakrishnan et al. (2006). 
However, one study confirmed by a 
simplified version of the Nottingham 
Health Profile that 69% of patients 
discharged from hospital were satisfied 
with their current health (Gopal et al. 
1997). Limitations in the physical 
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domain was the most common complaint 
in 42% of the patients taking part in the 
evaluation of HRQoL (Gopal et al. 
1997). Supporting evidence comes from 
another study, where loss of energy and 
limitations in physical mobility were the 
predominant complaints according to the 
Nottingham Health Profile six months 
after ARF (Korkeila et al. 2000). Another 
study reported that 77% of questionnaire 
respondents assessed their current health 
status as good or excellent (Morgera et 
al. 2002).  
The long-term effects of critical 
illness and intensive care on HRQoL 
observed in ARF patients are comparable 
with those seen in other critically ill 
patients. A study on heterogeneous ICU 
patients reported reduced general health 
and physical functioning, and increased 
pain six years after intensive care 
(Kaarlola et al. 2003). A study of 79 
mechanically ventilated patients reported 
HRQoL, as measured by the Nottingham 
Health Profile, to be significantly 
reduced compared with the normal 
population (Combes et al. 2003). In acute 
respiratory distress syndrome patients, 
several studies have documented 
decreased long-term HRQoL (Davidson 
et al. 1999; Schelling et al. 2000; 
Herridge et al. 2003; Orme et al. 2003). 
One year after intensive care, the HRQoL 
of patients with severe peritonitis 
remains lower than that of the general 
population, as measured by Short Form 
36 (SF 36) (Scheingraber et al. 2002). 
 
Prognostic factors 
ARF has been found to be an 
independent predictor of mortality (Levy 
et al. 1996; de Mendonca et al. 2000; 
Metnitz et al. 2002). Calculated 
likelihood ratios for the risk of death in 
ARF patients are 1.96 (95% CI 1.66-
2.32), 2.80 (95% CI 2.36-3.31), and 7.74 
(95% CI 6.77-8.85), respectively. 
Hospital mortality in ARF patients has 
been documented to be significantly 
higher than in nonARF ICU patients, 
63% vs. 16%, (Metnitz et al. 2002). The 
calculated difference in mortality in this 
study was 47% (95% CI 44-51%). 
Moreover, ICU mortality in ARF patients 
has been reported to be three times as 
high as in other ICU patients, 43% vs. 
14% (de Mendonca et al. 2000). The 
calculated difference in mortality was 
29% (95% CI 23-34%). In the same 
study, the calculated odds ratio for death 
was 1.59 (95% CI 1.23-2.06) for oliguric 
ARF. However, an odds ratio for death as 
high as 5.5 has also been reported in 
contrast media-induced ARF (Levy et al. 
1996) and as high as 6.6 in amphotericin 
B-induced ARF (Bates et al. 2001). 
Multiple organ dysfunction and other 
comorbidities contribute to the high 
mortality rate associated with ARF 
(Biesenbach et al. 1992). Independent 
predictors of ICU and hospital mortality 
have been described in numerous studies 
(Table 5). The most common factors 
directly related to ARF mortality are age, 
mechanical ventilation, other organ 
failures, and “late” occurrence of ARF. 
Renal recovery is usually good. It has 
been reported to be 78% (95% CI 68-
85%) at one year (Bagshaw et al. 2005). 
In critical illness, age and preadmission 
quality of life have been documented to 
be the main factors affecting HRQoL 
after ICU discharge (Vazquez Mata et al. 
1992; Wehler et al. 2001). One of the 
studies also showed that organ failures 
increased the risk for deteriorated 
physical health, but did not affect mental 
33
health, six months after hospital 
discharge (Wehler et al. 2001). The 
HRQoL was measured in this study using 
a scale validated by Fernandez et al. 
(1996). 
In these studies, the risk for death was 
expressed as odds ratios (ORs) and/or 
risk ratios (RRs) (Table 5). ORs compare 
the mortality rate with the survival rate in 
ARF vs. nonARF patients. ORs can be 
calculated as follows: 
RR represents the risk of death in 
patients with ARF compared with the 
risk in nonARF patients, and can be 
calculated as follows: 
 
Deceased ARF patients/All ARF patients 
Deceased nonARF patients/All nonARF patients 
However, in evidence-based medicine, 
the use of likelihood ratios (LRs) has 
been recommended over ORs or RRs in 
prognostic studies (Okada 2005). The 
advantage of LRs is that they can be 
combined with the pretest probability of 
death to calculate a total likelihood of 
death after the test. Positive likelihood 
ratios (LR+) represent the likelihood of 
death in ARF patients/the likelihood of 
death in nonARF patients, and can be 
calculated as sensitivity/1-specificity or 
as: 
 
Deceased ARF patients/All deceased patients 
1 – (Surviving nonARF patients/All surviving patients) 
In evidence based medicine calculating 
likelihood ratios retrospectively for 
studies, which have not reported them, is 
usually recommended. However, the 
majority of the studies included in Table 
4 did not report the exact number of 
patients in all their categories. Hence, 
LRs could not be retrospectively 
calculated, and ORs are reported in Table 
5. 
Several scoring systems have been 
developed to predict mortality in ARF 
(Liano et al. 1993; Paganini et al. 1996; 
Chertow et al. 1998; Lins et al. 2000, 
2004; Bellomo et al. 2001, 2004; Mehta 
et al. 2004) (Table 6). In all but two of 
these, hospital mortality is used in the 
prediction model. However, the 
classification by Chertow et al. uses 30-
day mortality in the prediction model and 
that by Paganini et al. fails to mention 
which mortality is used in the prediction 
model. The RIFLE classification 
(Bellomo et al. 2004) is presented in 
Table 2. All of these scoring methods 
performed well when they were validated 
in single-center studies for outcome 
prediction in ARF patients. However, 
when the same scoring methods were 
tested in a large multinational study, the 
predictive abilities of several turned out 
to be lower than those originally 
published (Uchino et al. 2005). The 
RIFLE classification has been evaluated 
by two studies, which have shown that 
the RIFLE stage Failure presents much 
higher mortality than the stages Risk or 
Injury (Abosaif et al. 2005; Bell et al. 
2005). Abosaif et al. found the difference 
in mortality between patients in stage 
Failure vs. other patients to be 27% (95% 
CI 12-42%). In the study by Bell et al., 
mortality was 58% in stage Failure vs. 
24% in stage Risk and 22% in stage 
Deceased ARF patients/Surviving ARF patients 
Deceased nonARF patients/Surviving nonARF patients 
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Injury. The Bellomo score (Bellomo et 
al. 2001) has been documented to 
correlate with mortality, but not to be an 
independent predictor for it (Ostermann 
et al. 2005). Ostermann et al. reported the 
ORs for death according to the Bellomo 
classification to be 0.18 (no ARF), 2.12 
(ARI), 4.8 (ARFS), 8.37 (SARFS), and 
2.4 (end-stage renal failure). The ability 
of general severity-of-illness scoring 
methods to predict outcome in ARF is 
unclear. Some studies have reported 
good ability for APACHE II score and 
the SOFA score (van Bommel et al. 
1995; Parker et al. 1998; Fiaccadori et al. 
2000; Chen et al. 2001; Peres Bota et al. 
2002), whereas others have provided 
contradictory data (Halstenberg et al. 
1997; Fiaccadori et al. 2000; Carbonell et 
al. 2004; Abosaif et al. 2005; Lima et al. 
2005). 
Most of the scores mentioned above  
were developed according to the 
recommendations for predictive tools 
(Laupacis et al. 1994; Ruttimann 1994), 
where the patient sample is a well-
defined cohort, univariate analysis is 
used to determine variables associated 
with mortality, the model’s discri-
minative power is determined by receiver 
operating characteristic (ROC) analysis, 
and the model is validated using 
multivariate analysis. However, two of 
the scores, RIFLE and Bellomo, are 
based on consensus and have not yet 
been validated.  
Several biomarkers, used in the 
diagnosis of ARF or in determining the 
pathogenesis of ARF, have also been 
tested for their ability to predict outcome 
in ARF (Simmons et al. 2004). The most 
commonly studied biomarkers are 
plasma/serum creatinine concentration, 
plasma urea concentration, and blood 
urea nitrogen (Paganini et al. 1996; 
Mehta et al. 2002; Lima et al. 2005).  
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Table 5. Major independent factors directly related to mortality in acute renal failure 
 (ARF). OR=odds ratio, RR=risk ratio, RRT=renal replacement therapy, 
 ICU=intensive care unit, APACHE II=Acute Physiology and Chronic Health 
 Evaluation II.  
Reference Independent predictors of mortality 
Groeneveld et al. 
1991 
Age, cardiovascular failure, pulmonary failure, RRT 
Brivet et al. 1996 Age, previous health status, hospitalization before ICU admission, late 
ARF, sepsis, oliguria, APACHE II score, number of failing organs 
Liano et al. 1996 Coma, assisted respiration, hypotension, jaundice, oliguria 
Paganini et al. 1996 Male gender, respiratory failure requiring mechanical ventilation, 
hematological dysfunction, bilirubin >2.0 mg/dL, absence of surgery, 
serum creatinine on first RRT day, increasing number of failing organs, 
increased blood urea nitrogen on admission 
Schwilk et al. 1997 Cardiovascular (OR 7.7)/ hepatic (OR 6.3)/ respiratory (OR 3.6)/ 
neurological failure (OR 3.0), massive transfusion (OR 5.3), age over 60 
years (OR 3.7) 
Chertow et al. 1998 Male gender (OR 3.70), oliguria (OR 4.39), mechanical ventilation (OR 
2.95), acute myocardial infarction (OR 5.90), acute stroke or seizure (OR 
7.35), chronic immunosuppression, hyperbilirubinemia, metabolic 
acidosis (OR 0.93) 
Behrend et al. 1999 Oliguria, mechanical ventilation, decreased cardiac function 
Mehta et al. 2002 Age (OR 1.02), male gender (OR 2.36), respiratory (OR 2,62)/ liver (OR 
3.06)/ hematological failure (OR 3.40), serum creatinine level (OR 0.71), 
blood urea nitrogen (OR 1.02), log urine output (OR 0.64), heart rate 
(OR 1.01) 
Hoste et al. 2003 Age, need for vasoactive therapy/ mechanical ventilation/ RRT 
Lins et al. 2004 Age, albumin, prothrombin time, respiratory support, heart failure, 
sepsis, bilirubin, hypotension 
Schroeder et al. 
2004 
Underlying disease, length of stay in ICU, use of catecholamines, late 
ARF, correlation of APACHE II score and ICU length of stay 
Bagshaw et al. 2005 Comorbidities, liver disease, APACHE II score, septic shock, RRT 
Lima et al. 2005 Age ≥65 years, blood urea nitrogen ≥70 mg/dL, septic origin of ARF, 
previous hypertension 
Ostermann et al. 
2005 
Nonsurgical admission, emergency surgery, late ARF, mechanical 
ventilation, number of organ failures 
Uchino et al. 2005 Use of vasopressors (OR 1.95), mechanical ventilation (OR 2.11), septic  
(OR 1.36) or  cardiogenic shock (OR 1.41), hepatorenal syndrome (OR 
1.87) 
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Table 6. Calculation of five ARF- specific scores for prediction of hospital /30-day 
 mortality. 
Reference Score Validation Max. score 
Liano et 
al. 1993 
(0.032 x age in decades) – (0.086 for male gender) – (0.109 for nephrotoxic 
origin) + (0.109 for oliguria) + (0.116 for hypotension) + (0.122 for 
jaundice) + (0.150 for coma) – (0.154 for consciousness) + (0.182 for 







et al. 1996 
(2 points for male gender) + (3 points for mechanical ventilation) + (3 
points for hematological dysfunction) + (3 points for bilirubin >2.0 mg/dL) 
+ (1 point for absence of surgery) + (0 points if no other organ failures/2 
points for 2-3 other organ failures/3 points for 3-7 other organ failures) + (1 
point for 0-50 mg/dL rise in blood urea nitrogen/2 points for >50 mg/dL 
rise in blood urea nitrogen ) + (3 points if SCr ≤2.0 mg/dL/1 point if SCr 





et al. 1998 
(0.6991 for male gender) + (0.8128 for oliguria) + (0.0557 x total bilirubin 
[mg/dL]) + (0.6215 for mechanical ventilation) + (1.1245 for stroke or 
seizure) + (1.1432 for acute myocardial infarction) + (0.8643 for chronic 






Lins et al. 
2000 
SHARF0: (7 x age in decades) + (6 x albumin category) + (3 x prothrombin 
time category) + (39 for respiratory support) + (9 for heart failure) + 52, 
SHARF48: (7 x age in decades) + (6 x albumin category) + (3 x 
prothrombin time category) + (43 for respiratory support at 48 h) + (16 for 
heart failure at 48 h) 
ROC, linear 
regression 
0h: 236,  
48h: 247  
Bellomo et 
al. 2001 
ARI: (PCr >1.6 mg/dL/ rise ≥0.8 mg/dL) and (P-urea >22 mg/dL/ rise >11 
mg/dL and/or urine output <800 mL/24 h/<200 mL/6h), ARFS: (PCr >3.1 
mg/dL /rise ≥1.6 mg/dL) and (P-urea >45 mg/dL/ rise >22 mg/dL and/or 




Lins et al. 
2004 
SHARF II0: (3.0 x age in decades) + (2.6 x albumin category) + (1.3 x 
prothrombin time category) + (16.8 for respiratory support) + (3.9 for heart 
failure) + (2.8 x bilirubin in mg/dL) + (27 for sepsis) + (21 for hypotension) 
-17, SHARF II48: (3.9 x age in decades) + (3.3 x albumin category) + (1.7 x 
prothrombin time category) + (23.7 for respiratory support at 48 h) + (8.8 
for heart failure at 48 h) + (2.5x bilirubin in mg/dL) + (24 for sepsis) + (17 







(0.0170x age) + (0.8605 for male gender) + (0.0144 x blood urea nitrogen) 
– (0.3398 x creatinine) + (1.2242 for hematological failure) + (1.1183 for 
liver failure) + (0.9637 for respiratory failure) + (0.0119 x heart rate) – 






SCr=serum creatinine concentration, RRT=renal replacement therapy, SHARF=Stuivenberg Hospital Acute Renal 
Failure scoring system, ARI=acute renal injury, ARFS=acute renal failure syndrome, SARFS=severe ARFS, P-
urea=plasma urea concentration, ROC=receiver operating characteristic, Max. score=maximum score.
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3. AIMS OF THE STUDY 
The general aim was to evaluate the outcome of critically ill patients with ARF and factors 
related to outcome. Predictive tools in the development of ARF and the mortality of ARF 
patients were investigated.  Specific objectives were as follows: 
 
1. To evaluate two newly proposed definitions of ARF in assessing the 
 severity of illness (I). 
 
2. To determine the evolution of laboratory markers and pro- and anti-
 inflammatory cytokines in ARF (II-III), specifically: 
 
a) to determine the evolution of monocyte HLA-DR expression (II), and 
 plasma concentrations of interleukins 6, 8, and 10 in critically ill SIRS 
 patients with  ARF (II), 
 
b) to determine the evolution of serum cystatin C in critically ill patients 
 with ARF (III), and to compare the diagnostic accuracy of serum cystatin C 
 with plasma creatinine in development of ARF (III). 
 
3. To evaluate possibilities of affecting the development of ARF by studying 
 the effect of intermittent hemodiafiltration on myoglobin elimination from 
 plasma in severe rhabdomyolysis (IV). 
 
4. To assess the outcome of critically ill patients with ARF (I-III, V), in terms 
 of short-term (I-III, V) and long-term mortality (V) and HRQoL (V).  
 
5. To evaluate prediction of outcome in critically ill patients with ARF (I-III): 
 by two ARF-specific severity scores (I), by monocyte HLA-DR 
 expression and plasma concentrations of interleukins 6, 8, and 10 (II), and by 
 serum cystatin C concentration (III). 
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4. SUBJECTS AND METHODS 
 
4.1. Patients 
Inclusion criteria and formation of 
the study population 
Altogether 1662 patients were included 
in the study. The number of treatment 
episodes was 1691, with 29 patients 
having two separate episodes. The 
flowchart of Studies I-V is presented in 
Figure 1. Twenty-seven of the patients 
were included in two studies. Twenty-six 
patients were first included in Study II 
and then in Study V. One patient was 
first included in Study III and then in 
Study V. However, the study designs and 
endpoints differed from each other. 
Studies II and III were prospective, 
assessing predictive factors for outcome, 
and the Study V was retrospective, 
evaluating the HRQoL after ARF. 
Characteristics of the study population 
are shown in Table 7. 
Study I comprised 668 consecutive 
adult patients admitted to two ICUs 
within 11 months in 2005. During this 
time 26 patients had two separate 
treatment periods, the earlier one of 
which was included in the primary 
analysis. The secondary analysis 
included all 694 consecutive treatment 
episodes. Nine dialysis-dependent 
patients with chronic end-stage renal 
failure and two patients receiving RRT 
for nonrenal reasons were excluded. The 
final study population consisted of 658 
patients with 683 treatment episodes.  
Study II included a total of 103 
consecutive adult ICU patients admitted 
in 1998-1999 with systemic inflam-
matory response syndrome (SIRS). SIRS 
was defined according to the consensus 
criteria presented by Bone et al (1992): 
temperature >38ºC or <36ºC; heart rate 
>90 beats /min; respiratory rate ≥20 
breaths /min or PaCO2 <4.3 kPa; white 
blood cell count >12x109 cell/L or 
<4x109 or >10% immature forms. SIRS 
was verified by the presence of two or 
more of the criteria. 
Study III consisted of a total of 199 
consecutive adult ICU patients admitted 
during a period of nine months in 2003. 
Three patients had two separate treatment 
episodes and were included twice in the 
study, resulting in the total number of 
treatment episodes of 202. The separate 
treatment episodes were handled as 
separate patients, as the episodes were 
clearly distinct temporally. One of those 
episodes ended up in the ARF group and 
five in the nonARF group. Table 8 





Table 7. Demographics of the study population. 
Values are presented as median (interquartile range) or number (%). ARF= acute renal failure. RIFLE= 
Risk, Injury, Failure, Loss of renal function, End-stage renal disease, ICU=intensive care unit, APACHE 
II= Acute Physiology and Chronic Health Evaluation II, SOFA= Sequential Organ Failure Assessment. 
*p<0.05 
 
Table 8. Indications for intensive care in patients with and without acute renal failure 
 (ARF) in Study III. 
Values are presented as number of patients (percentage) and compared by Χ2-test. NS = not significant 
 
Study I (n=658) Study II (n=103) Study III (n=202) Study VI  Study V  
ARF             NonARF 
(n=74)            (n=584) 
 ARF         NonARF 
(n=36)           (n=67) 
 ARF          NonARF  

































































































Indication for intensive care ARF patients (n=54) NonARF patients (n=148) p 
Sepsis 19 (35.2%) 21 (14.2%) 0.001 
Other infection 11 (20.4%) 36 (24.3) NS 
Other noninfectious state 24 (44.4%) 91 (61.5%) 0.03 
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Study IV included 16 adult 
emergency patients with rhabdomyolysis 
treated in an acute renal replacement unit 
between July 2002 and November 2005. 
Inclusion criteria were the presence of 
rhabdomyolysis and plasma myoglobin 
concentration over 10 000 µg/L at the 
time of allocation. All eligible patients 
were recruited, and none refused to 
participate. However, one patient died 
less than one hour after the first 
intervention commenced and another 
patient was lost after the first 
intervention because some of the 
laboratory samples were lost. These 
patients were considered deviations from 
the protocol.  
Study V comprised 703 patients 
receiving RRT for ARF during 1998-
2002 at Helsinki University Central 
Hospital. Indications for RRT were 
presence of ARF defined as an acute 
increase in serum creatinine to at least 
500 µmol/L or plasma urea over 35 
mmol/L (38%) or a sudden rise in serum 
creatinine over 50 µmol/L and oliguria 
/anuria /severe metabolic acidosis 
/hyperpotassemia (59%) or rhabdo-
myolysis with oliguria and no response 
to forced alkaline diuresis (3%). Twenty-
two patients were excluded because the 
Population Register Centre could not 
verify their status (dead or alive). Hence, 
681 patients ultimately participated. In 
Study V, two patients were included 
twice as they had separate treatment 
episodes far apart from each other.  
 
Definitions for acute renal failure 
In Study I, ARF was defined according 
to two methods for defining and scoring 
the severity of illness in ARF: the RIFLE 
classification (Bellomo et al. 2004) and 
the Bellomo classification  (Bellomo et 
al. 2001). The RIFLE classification 
defines five stages (Table 2), and the 
Bellomo classification three stages of 
ARF (Table 1). Patients treated with 
RRT for renal indications were 
considered to have ARF (stage “Failure”/ 
stage “severe acute renal failure 
syndrome”) regardless of their serum 
creatinine concentration or urine output. 
The RIFLE classification does not 
include precise criteria for RRT patients. 
On the other hand, the classification also 
does not clearly state that RRT should be 
ignored. The interpretation of the RIFLE 
criteria in Study I was based on one of 
the documents in the Acute Dialysis 
Quality Initiative website concerning 
ARF research and the definition of ARF. 
This states that all patients needing acute 
RRT for renal reasons should be 
considered as having acute renal failure 
(www.ccm.upmc.edu/adqi/adqi02.html, 
1. Defining acute renal failure, Work 
Group Report) (Bouman C et al. 2003). 
The RIFLE definition was also used in 
Study III, where patients were classified 
as having ARF if they fulfilled the 
RIFLE criteria for stage “Failure”. In 
Study II, patients were considered to 
have ARF if they met the SOFA score 
criterion (2 points or more) for ARF: 
serum creatinine levels higher than 170 
µmol/L (2.0 mg/dL) (Vincent et al. 
1996). None of the patients had a known 
history of chronic renal failure, nor had 
they ever received any form of RRT, and 
hence, no criteria for “acute on chronic” 
ARF were needed. In Study IV, the 
incidence of ARF was not recorded since 
all patients received prophylactic RRT as 
part of the protocol. In Study V ARF, 
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was defined as the need for acute RRT 




Study I. A prospective cohort of 668 
consecutive patients treated in two ICUs 
of a tertiary care hospital was 
investigated. The prevalence of ARF was 
calculated and classified according to the 
RIFLE (Bellomo et al. 2004) and the 
Bellomo (Bellomo et al. 2001) classi-
fications. In patients with a history of 
plasma creatinine level above the upper 
range limit (above 100 µmol/L [1.1 
mg/dL] in males and above 90 µmol/L 
[1.0 mg/dL] in females) in our labo-
ratory, the severity of ARF was scored 
using “acute on chronic” criteria. In 48 
patients, the baseline steady-state plasma 
creatinine concentration could not be 
obtained from previous hospital records 
and was estimated using the Modification 
of Diet in Renal Disease (MDRD) 
formula; GFR (mL/min/1.73m2) =
exp(5.228-1.154 x ln(SCr)-0.203 x 
ln(age)-(0.299 if female)+(0.192 if 
African-American)) (Levey et al. 1999). 
The ability of the RIFLE and the 
Bellomo classifications to predict 
mortality was tested, and compared with 
APACHE II (Knaus et al. 1985) and 
SOFA (Vincent et al. 1996) scores. 
Hospital mortality rate was recorded. 
Study II. This was a cohort study that 
included 103 adult patients with SIRS 
from two university hospital ICUs who 
were prospectively enrolled in the study 
within 24 h of admission to the ICU. 
Monocyte expression of histocompa-
tibility leukocyte antigen-DR (HLA-DR), 
and plasma levels of pro- and anti-
inflammatory cytokines (IL-6, IL-8, and 
IL-10) and their predictive value in 
prediction of hospital mortality were 
assessed. Severity of illness was 
determined by calculating APACHE II 
score on admission and SOFA score for 
days 1-3. Mortality rate was assessed 28 
days after admission to ICU.  
Study III. A prospective cohort of 
199 patients (202 treatment episodes) 
treated in a university hospital ICU was 
investigated. Serum cystatin C, plasma 
creatinine, and plasma urea were 
evaluated as markers of renal function in 
ARF, and their power in predicting 
mortality of ARF patients was assessed. 
Severity of illness was determined by 
calculating admission APACHE II score 
and SOFA score daily during the ICU 
stay. Hospital mortality rate was 
assessed. 
Study IV. This was a prospective, 
controlled, cross-over study. Sixteen 
emergency patients who met the 
inclusion criteria of rhabdomyolysis and 
plasma myoglobin concentration over 
10 000 µg/L, were allocated into two 
groups after written consent had been 
obtained. Forced alkaline diuresis was 
started immediately after allocation and 
continued throughout the study. HDF, 
which lasted for four hours, was started 
in group A immediately after allocation 
and in group B four hours later. The 
effect of HDF versus forced alkaline 
diuresis alone on plasma myoglobin 
clearance in rhabdomyolysis was studied. 
The primary outcome measure was the 
percentual decrease in plasma myoglobin 
concentration during the intervention. 
The plasma concentration of myoglobin 
was plotted against time (0-4 hours) for 
HDF and forced alkaline diuresis. The 
area under the curve (AUC0-4h) was 
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calculated by using the trapezoidal 
method. The sieving coefficient for 
myoglobin and the myoglobin clearance 
rate were determined. The sieving 
coefficient for myoglobin was calculated 
from the equation: S= Cf/Cw, where Cf
represents the concentration of myo-
globin in the filtrate. Cw represents the 
concentration of myoglobin at the 
membrane surface, which was calculated 
from the difference in pre- and post-filter 
concentrations of myoglobin. Myoglobin 
clearance (K) was calculated by multi-
plying the sieving coefficient with 
ultrafiltration rate, which was 10.25 L/h 
(170.83 mL/min): K= S x 170.83 
mL/min. Because of the cross-over 
design of the study and easily recog-
nizable natures of the two interventions, 
neither patients nor researchers were 
blinded. One researcher enrolled the pa-
tients in the study and supervised the 
HDF procedure and another performed 
the statistical analysis. Urinary alkaliza-
tion was carried out by the clinician on 
duty, who was not part of the research 
team. All other interventions for rhabdo-
myolysis, except the study interventions, 
were not allowed. Severity of illness was 
assessed by calculating APACHE II and 
SOFA score for the allocation day. The 
primary analysis was intention-to-treat. 
All patients who underwent random 
allocation were analyzed according to 
their original group assignment. Missing 
data were handled by imputing values 
using the group average/last observed 
response. Fourteen patients remained for 
the per-protocol analysis since two 
patients in group A were considered 
protocol violators. 
Study V. This was a cross-sectional 
cohort study with 703 patients who had 
received RRT for ARF during 1998-2002 
either in an ICU or in an acute RRT unit 
at a university hospital. The Central 
Population Registry of Finland confir-
med the number of ARF patients alive 
and living in Finland in June 2003 and 
again in May 2004. Long-term survival 
was determined after a median follow-up 
of 3.9 years, which was defined as the 
time between the onset of RRT and the 
date of confirmation of the patient’s 
status (alive or dead) by the Central 
Population Registry.  
The HRQoL of survivors was 
evaluated after a median follow-up of 2.4 
years using a validated Finnish version of 
a generic, standardized, multidimensional 
health questionnaire: the EuroQol five 
dimensions, (EQ-5D) (Brooks R 1996).  
The survivors received the questionnaire 
by mail in August 2003. Enclosed was a 
letter explaining the purpose of the study, 
a written consent form, and the EQ-5D 
instrument of HRQoL. The HRQoL of 
the survivors was then compared with an 
age- and gender-matched Finnish general 




Plasma / serum creatinine (I-V). 
Plasma creatinine concentrations were 
analyzed using fully automated enzy-
matic assays (Hitachi Modular, Roche, 
Tokyo, Japan). Serum concentrations 
were measured in Study II and plasma 
concentrations in other studies. In 
Helsinki University Central Hospital, the 
upper normal range limit for plasma 
creatinine concentration in males was 
changed in 2004. The upper range limit 
for plasma creatinine concentration in 
males was therefore different in Studies I 
44
Table 9. Design of Studies I-V. 
ARF=acute renal failure, IL=interleukin, HLA-DR=Histocompatibility leukocyte antigen-DR, 
HDF=hemodiafiltration, FAD=forced alkaline diuresis.      
 
and III. In Study I, plasma values less 
than 100 µmol/L were considered normal 
and in Study III less than 95 µmol/L. In 
females, plasma values less than 90 
µmol/L were considered normal. 
Plasma urea (I, III-V). Plasma urea 
concentrations were analyzed using fully 
automated enzymatic assays (Hitachi 
Modular, Roche, Tokyo, Japan). Values 
less than 10 mmol/L were considered 
normal. 
Plasma concentrations of inter-
leukins 6, 8, and 10 (II). The blood for 
cytokine analyses was collected into 
EDTA tubes, centrifuged, and stored at –
70ºC until analyzed. Plasma levels of IL-
6, IL-8, and IL-10 were determined as 
duplicates by commercial enzyme immu-
noassays according to the manufacturer’s 
instructions (CLB, Amsterdam, Nether-
lands). Laboratory data were collected on 
the day of admission and two days 
thereafter. 
Monocyte HLA-DR expression (II). 
The blood for HLA-DR analysis was 
collected into EDTA tubes, centrifuged, 
and stored at –70°C until analyzed. For 
flow cytometry, fresh 100 µL aliquots of 
the EDTA blood samples were triple-
stained at 4ºC with pre-titrated amounts 
of CD14-FITC, HLA-DR-PE (IgG2a), 
and CD45-PerCP antibodies. Control 
samples were stained with CD14-FITC, 
irrelevant IgG2a-Pe, and CD45-PerCP, 
accordingly. All antibodies were from 
Becton Dickinson, San Jose, CA, USA. 
After incubation, erythrocytes were lysed 
by the addition of diluted FACS lysing 
solution (Becton Dickinson), and stained 
leukocytes were washed with phosphate-
buffered saline supplemented with 0.1% 
NaN3.  Samples were analyzed on a 
Study No of 
Patients 
Design Interventions Object 
I 668 Prospective, cohort, 
unselected patients 
None Comparison of ARF-specific scores 
in prediction of hospital mortality 
II 103 Prospective, cohort, 
SIRS patients 
None Evaluation of IL-6, IL-8, IL-10 and 
HLA-DR expression in prediction of 
28-day mortality 
III 199 Prospective, cohort, 
unselected patients 
None Evaluation of cystatin C in prediction 
of ARF/hospital mortality 
IV 16 Prospective, 
controlled, cross-over 
HDF vs. FAD Comparison of HDF and FAD in 
plasma myoglobin elimination rate 
V 703 Retrospective, cohort, 
unselected patients 
Assessment of  
health-related 
quality of life  
Evaluation of long-term survival and 
quality of life after ARF 
45
FACsort or FACS calibur flow cytometer 
using CellQuest software (Becton 
Dickinson). A total of 5000 events were 
collected in a live gate combining CD 
14-positive events and the monocyte area 
in a light scatter dot plot. Events 
collected were analyzed in a FL1/FL2 
dot plot. Markers discriminating between 
negative and positive FL2 events were 
set to allow for approximately 1% 
positive events in the control sample. 
HLA-DR-expressing monocytes were 
expressed as a percentage of the total 
number of CD14-positive monocytes. 
Color compensation was checked on a 
daily basis using aliquots of normal 
EDTA blood samples stained with CD3-
FITC, -PE, and/or –PerCP. Laboratory 
data were collected on the day of 
admission and two days thereafter. 
Serum cystatin C (III, IV). Serum 
cystatin C was analyzed using a fully 
automated immunonephelometric met-
hod (BN II, Dade Behring, Marburg, 
Germany). Values less than 1.04 mg/L 
were considered normal. In Study III, 
serum cystatin C was measured on 
admission, daily for the first three days, 
and 5-7 times a week for the rest of the 
ICU stay. In Study IV, serum cystatin C 
concentration was measured once before 
initiation of intervention. 
Plasma myoglobin (IV). Arterial 
plasma myoglobin concentration was 
measured at allocation and every two 
hours during the interventions using a 
fully automated photometric and 
immunochemical method. 
Scoring methods for the severity 
of illness 
1. GENERAL (I-V) 
To evaluate the general severity of 
illness, APACHE II (Knaus et al. 1985) 
and SOFA (Vincent et al. 1996) scores 
were used. The APACHE II score was 
calculated on admission (I-III), except in 
studies IV-V, where it was calculated on 
the day of allocation and on the day 
when RRT commenced, respectively. 
The SOFA score was mainly calculated 
daily (I, III) or daily for the first three 
days (II), but in Study IV it was 
calculated on the day of allocation and in 
Study V on the day when RRT 
commenced. In Study I, APACHE II and 
SOFA scores were used as references for 
the two ARF-specific scores studied.  
 
2. ARF-SPECIFIC SCORES (III) 
Scoring of the severity of ARF in Study I 
was done by two specific scoring 
methods for ARF: the RIFLE 
classification and the Bellomo 
classification. These methods were 
chosen as they cover a wide range of 
severities of illness and are therefore 
both sensitive and specific. Both scoring 
systems have specific criteria for “acute 
on chronic” ARF as well. The RIFLE 
classification defines five stages (Table 
2), and the Bellomo classification three 
stages of ARF (Table 1).  
 
Interventions 
The intervention protocol for rhabdo-
myolysis patients in Study IV was as 
follows: fluid replacement with NaCl 
0.9% 1000mL per hour and urinary 
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alkalization with NaHCO3 100 mL per 
hour as soon as the patient was diagnosed 
with rhabdomyolysis and considered 
eligible for the study. A RRT catheter 
(Mahurkar 11.5 Fr) was placed in the 
right vena jugularis interna. Invasive 
hemodynamic monitoring was started to 
maintain a central venous pressure (CVP) 
of 12-14 mmHg and mean arterial blood 
pressure of 75 mmHg. When adequate 
CVP was reached, fluid replacement was 
reduced to 400 mL per hour and NaCl 
0.9% was replaced by NaCl 0.35% and 
glucose 0.5%. Intravenous furosemide 
was administered if CVP rose above 14 
mmHg to avoid fluid overload. Nor-
epinephrine (2 mg in 100 mL of 0.5% 
glucose) infusion was initiated if 
necessary to maintain mean arterial blood 
pressure of 75 mmHg.  
HDF (4008H Fresenius) was delive-
red using a predilution mode with an FX-
100 dialyzer and a bicarbonate-based so-
lution as a replacement. Figure 2 shows 
the principle of the hemodiafiltration sys-
tem. Ultrafiltrate (1000 mL in four hours) 
was replaced to maintain a zero balance. 
Dalteparin 5000 ky was given as a bolus 
for anticoagulation before HDF was 
started, and an extra bolus of 2500 ky 
was given during HDF if necessary. 
Anticoagulation activity was monitored 
by measuring arterial anti-fXa every two 
hours during HDF. The total amount of 
filtrated myoglobin was measured from 
the 161 L of filtrate at the end of HDF.    
FAD was carried out by adminis-
tering sodium bicarbonate 1.4% 50-100 
mL per hour to maintain urine pH of at 
least 7.5 and urine output above 400 mL 
per hour. Urine alkalization was 
continued also during HDF. 




1. MORTALITY (I-III, V) 
Short-term mortality (I-III). These 
comprised 28-day mortality (II) and 
hospital mortality (I, III).  
Long-term mortality (V). The 
Central Population Registry of Finland, 
which maintains a record of all deaths 
and current addresses of Finnish citizens, 
confirmed the number of ARF patients 
alive and living in Finland in June 2003 
and again in May 2004. The follow-up 
time was defined as the period between 
the onset of RRT and the date of 
confirmation of the patient’s status (alive 
or dead) by the Central Population 
Registry.  This resulted in a follow-up 
time for mortality of 1.4-6.4 (median 3.9, 
interquartile range 2.5-5.0) years. 
 
2. QUALITY OF LIFE (V) 
The EuroQol five dimensions (EQ-5D), a 
generic, standardized, multidimensional, 
self-administered instrument, was used to 
measure HRQoL in Study V. The EQ-5D 
includes five dimensions (mobility, self-
care, usual activities, pain/discomfort, 
anxiety/depression) evaluated on a 1-3 
scale. These dimensions are described in 
detail in Table 16 (page 63).  The 
instrument utilizes a set of population-
based preference weights to calculate a 
single index score representing the 
overall HRQoL, which facilitates 
comparison with the age- and gender-
matched general population.  The EQ-5D 
instrument was chosen for this study 
because of its multidimensionality and 
subjective expression of a patient’s 
health, both widely accepted criteria for 
HRQoL measurement. In 2002, the EQ-
5D was assessed as suitable for 
measuring HRQoL in critical care at the 
Brussels Roundtable meeting (Angus et 
al. 2003). The EQ-5D instrument also 
includes a visual analog scale (VAS) for 
self-rating of patients’ health, ranging 
from 0 to 100 (representing the worst and 
best states imaginable). Respondents rate 
their health state by drawing a line to the 
appropriate point on the VAS scale. For 
HRQoL, the follow-up time was between 
0.6 and 5.6 (median 2.4, interquartile 
range 1.2-3.8) years in Study V. 
 
3. QUALITY-ADJUSTED LIFE- YEARS (V) 
In Study V, quality-adjusted survival was 
calculated for the first year by 
multiplying the EQ-5D index score by 
the one-year survival, and for the entire 
survival period by multiplying the EQ-
5D index score by the total survival time. 
The costs per quality-adjusted life-year 
were calculated using the total costs of 
hospital treatment per patient. Direct 
secondary healthcare costs to the 
provider were obtained from the 
Ecomed® clinical patient-level costing 
and analyzer system (Datawell Ltd., 
Finland), where all cost data concerning 
treatment of individual patients in the 
hospital are stored. For patients treated 
before the year 2000, the total costs of 
hospital treatment were approximated 
using the information for the year 2000. 
Indirect costs (e.g. post-hospitalization 
costs or increased costs for basic 
healthcare) were not included in the 
calculation. For intermittent RRT, the 
costs of treatment were summed directly 
from hospital billing records. For CRRT, 
the costs of treatment were calculated by 
combining the costs of dialysis 
equipment, fluids, filters, venous access 
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catheters, etc., and the wages of nursing 
staff. 
 
4. PREDICTION OF OUTCOME (I-III) 
The development process of validating 
predictive tools has been reviewed by 
Ruttimann (1994). For model identi-
fication, the association of possible 
significant risk factors with outcome is 
first tested by univariate data analysis. 
Receiver operating characteristic (ROC) 
analysis is recommended to test the 
model’s discriminative power for the 
selected outcome. For model calibration, 
multivariate data analysis, such as 
logistic regression analysis, is used.  
In Studies I-III, where predictive 
variables for mortality were tested, the 
study population consisted of an 
unselected heterogeneous cohort 
population of ICU patients, as recom-
mended by the Evidence-Based Medicine 
Working Group (Laupacis et al. 1994). 
The Mann-Whitney U-test and Χ2-test, 
were used as appropriate, to identify 
factors associated with mortality. 
Variable’s power to discriminate 
between survivors and nonsurvivors was 
tested by ROC analysis. Forward 
stepwise logistic regression analysis was 
used to test the variable’s ability to 
independently predict mortality. 
Likelihood ratios for hospital mortality 
were determined in Study I as 
recommended by the Evidence-Based 




The amount of missing data was 
determined in all studies. A p-value of 
less than 0.05 was considered significant, 
except in multiple comparisons, where 
Bonferroni corrections were calculated. 
Statistical analysis was performed using 
SPSS® 10.1.3 and 12.0.1 for Windows 
(SPSS Inc., IL, USA).  
 
SAMPLE SIZE CALCULATION (I-V) 
In Studies I and V, a sample of ap-
proximately 700 consecutive patients 
were collected. The appropriate sample 
size was approximated based on clinical 
experience. In Studies II and III, an 
adequate sample size was determined 
based on previous mortality rates and 
prevalence of ARF in the ICU. In Study 
IV, power analysis was performed to 
estimate an adequate sample size for 
revealing a clinically significant differ-
rence in plasma myoglobin decrease 
between the two treatment arms with a 
probability of 95% and a power of 80%. 
The decrease in plasma myoglobin 
concentration was approximated to be 
12 000 µg/L during HDF and 6000 µg/L 
during FAD with a standard deviation of 
the difference of 6000 µg/L. As a result, 
15 patients were approximated to be 
sufficient, and final sample size was 16 
patients. 
 
DATA CONSIDERATIONS (I-V) 
The Kolmogorov-Smirnov test and 
the Shapiro-Wilk test were used to 
evaluate the variables for normality. Data 
were not normally distributed in any of 
the studies, and thus, nonparametric tests 
were applied. A normalization procedure 
was carried out by 1/X normalization for 
plasma myoglobin concentrations and by 
logarithmic normalization for urine 
output for the analysis of variance in 
Study IV. 
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TESTS FOR COMPARING POPULATIONS 
Χ2-test (I-V): Χ2-test is used to test 
differences between two categorical 
variables. Here, it was used to compare 
patients’ demographic data. Moreover, in 
Study I, Χ2-test was applied to determine 
whether mortality differed in different 
stages of ARF. 
Fisher’s exact test (V): Fisher’s 
exact test was used instead of Χ2-test 
when the expected number of cases in 
any variable classes was less than five. 
The one-year mortality rates of patients 
treated in the ICU versus in the hospital 
wards were compared by Fisher’s exact 
test in Study V.  
Mann-Whitney U-test (I-V): The 
Mann-Whitney U-test was used to 
compare continuously distributed data of 
two independent populations. It was also 
used to test patients’ demographic data in 
all studies. Moreover, it was applied to 
evaluate differences between patients 
with and without ARF in studies II and 
III, AUCs (0-4 h), sieving coefficients 
for myoglobin, and myoglobin clearance 
rates in Study IV, and the HRQoL of 
patients treated in ICU versus in the 
acute dialysis unit in Study V.  
Wilcoxon signed-rank test (V): In 
Study V, the EQ-5D index scores of the 
study population were compared with 
those of the age- and gender-matched 
Finnish general population by the 
Wilcoxon-signed rank test, which is used 
to compare differences between paired 
groups if data distribution is categorical 
or continuous. 
Kruskal-Wallis test (V): The 
Kruskal-Wallis test was used to compare 
continuously distributed data of several 
independent populations. In Study V, the 
study population was divided into three 
age groups (≤50 years, 51-65 years, >65 
years), and the Kruskal-Wallis test was 
used to compare EQ-5D scores and VAS 
scores between age groups. 
Kendall’s W-test (I): Kendall’s W-
test was applied to compare the 
distributions of several related samples. 
It was used to test the similarity of an 
individual patient’s distribution across 
the ARF severity stages in study I. 
Coefficient W (Wa) measures concor-
dance and may vary from 0 to 1, value 0 
indicating total disagreement between 
distributions and value 1 total agreement 
between distributions. 
Analysis of variance (ANOVA)
(IV): ANOVA was used in Study IV to 
test the hypothesis that the means for the 
study groups come from the same 
sampling distribution of means. Repeated 
measures ANOVA included plasma 
myoglobin concentrations over time, 
treatment period, and intervention group 
as variates, and total urine output for 12 
hours as a covariate. The presence of a 
significant carry-over effect was 
excluded by including an intervention 
period in the ANOVA procedure.  
 
TESTING PREDICTIVE ABILITY 
Sensitivity and specificity (I): Sensi-
tivity and specificity for mortality were 
calculated in Study I for each separate 
stage of the RIFLE and Bellomo 
classifications (Table 10). 
Sensitivity was calculated as follows: A / 
(A+C). 




Table 10. Two-way table for 
 calculation of sensitivities,  
 specificities, and likelihood 
 ratios in Study I. 






Number of patients 
fulfilling the criteria A B
Number of patients 
not fulfilling the 
criteria 
C D
Likelihood ratios (I): In Study I, 
positive likelihood ratios for death, 
representing the likelihood of death 
divided by the likelihood of survival, 
were calculated as follows: sensitivity / 
(1-specificity). Likelihood ratios were 
calculated for each stage of the RIFLE 
and Bellomo maximum scores during the 
first three days in the ICU. The total 
likelihood for death at each stage was 
determined by multiplying the likelihood 
for death, without knowing the renal 
status of the patient, with the calculated 
likelihood ratios.  
Logistic regression analysis (I-III, 
V): In studies I-III and V, independent 
predictors for mortality were tested by 
logistic regression analysis since the 
outcome variable was dichotomous. In 
Study I, the analysis included admission 
day scores for RIFLE, Bellomo, 
APACHE II, and SOFA, and maximum 
scores for the first three days for RIFLE 
and Bellomo scores. In Study II, the 
analysis included admission day 
laboratory values. In Study III, the 
analysis included patient’s age, day 1 and 
maximum serum cystatin C and plasma 
creatinine concentrations, APACHE II 
and SOFA scores, need for corticosteroid 
therapy, and development of ARF. In 
Study V, the one-year mortality of 
patients treated in the ICU versus in the 
hospital wards and of patients treated in 
different years (1998-2002) was 
analyzed. APACHE II and SOFA scores, 
age, sex, and mode of RRT were used as 
variates, and treatment unit and treatment 
year as covariates in the analysis. 
Receiver operating characteristic 
(ROC) analysis (I-III): In ROC analysis, 
the results are expressed as an area under 
the curve (AUC), where the curve 
represents the relationship between 
sensitivity and (1-specificity) (Hanley et 
al. 1982). It can also be expressed as the 
relationship between the fraction of true 
positives and the fraction of false 
positives. The predictive power of a 
variable is expressed as an AUC; the 
greater the AUC, the better the predictive 
ability. An AUC value of 0.5 represents a 
predictive ability equivalent to tossing a 
coin or a 50-50 chance. In studies I-III, 
the power of the studied variables to 
discriminate between survivors and 
nonsurvivors was determined by ROC 
analysis, where mortality was used as a 
dependent variable; and the investigated 
variables as independent variables. In 
Study II, the results of the Mann-
Whitney U-test were used to select 
variables for the ROC analysis; only 
variables with significant differences 
between ARF and nonARF patients were 
selected. These variables included 
monocyte HLA-DR expression on days 
1-3, plasma levels of IL-6 on days 2 and 
3, plasma levels of IL-8 on days 1-3, and 
plasma levels of IL-10 on day 2. 
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OTHER TESTS  
Z-scores (V): Z-scores are calculated 
from the mean values of a study 
population and a standard population. It 
describes the difference in means of the 
study population and the standard 
population as the number of standard 
deviations. Z-scores in Study V were 
calculated for EQ-5D index scores and 
VAS scores.   
Spearman’s correlation (II-III, V): 
Spearman’s correlation coefficients were 
computed to examine the linear 
relationships between variables in studies 
II and III. In Study II, the correlation 
between monocyte HLA-DR expression 
and interleukin plasma values on day 1 
was tested. In Study III, the correlations 
between serum cystatin C concentrations 
and plasma creatinine and urea 
concentrations on days 1-10 were tested. 
Spearman’s correlation coefficients were 
computed to identify correlations 
between variables and HRQoL. 
Kaplan-Meier test (V): The morta-
lity over time of ARF patients receiving 
RRT during the treatment period was 
investigated by Kaplan-Meier survival 
analysis in Study V.  
 
Ethical aspects 
The study protocols were approved by 
the institutional Ethics Committee. 
Informed consent was obtained from 
each patient or their next of kin in studies 
IV and V. The Ethics Committee waived 
the need for informed consent in studies 
I-III. In Study IV, although the effect of 
FAD on myoglobin removal from plasma 
has not been proven, comparison of HDF 
with no treatment was considered 
unethical. The effect of HDF was 
therefore compared with the best 
available clinical practice, as 
recommended for all new treatments in 
clinical studies in critically ill patients. 
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5. RESULTS 
5.1. Prevalence of acute renal 
failure (I-IV) 
 
Table 11. Patients in Study I (n=658) 
 stratified according to the 
 RIFLE and Bellomo 
 classifications (maximum 
 points during the whole ICU 
 period). 
 ARF= acute renal failure, RIFLE= risk, injury, 
failure, loss of renal function, end-stage renal 
disease, ARI= acute renal injury, ARFS= acute 
renal failure syndrome, SARFS= severe acute 
renal failure syndrome. 
According to the results of Studies I and 
III, the incidence of ARF (defined as 
stage “Failure” according to the RIFLE 
classification) in a heterogeneous 
critically ill patient population during the 
whole ICU stay was 128/857 patients 
(15%, 95% CI 13-17%): 74/658 patients 
(11%, 95% CI 9-14%) in Study I and 
54/199 patients (27%, 95% CI 21-34%) 
in Study III. Incidence of ARF in patients 
with SIRS / sepsis was determined in 
Study II, where the incidence for ARF 
was 36/103 (35%, 95% CI 26-45%). The 
incidence of ARF in patients with severe 
rhabdomyolysis was 6/16 patients 
(37.5% 95% CI 18-62%) (Study IV). The 
distribution of patients in Study I across 
the separate stages of renal dysfunction 
according to the RIFLE and Bellomo 
definitions is presented in Table 11.  
 
5.2. Cytokines and monocyte 
human histocompatibility 
leukocyte antigen-DR (HLA-
DR) expression in acute renal 
failure (II) 
In critically ill patients with SIRS/sepsis, 
the plasma concentrations of several pro- 
(IL-6, IL-8) and anti-inflammatory 
cytokines (IL-10) were significantly 
higher in ARF than nonARF patients. In 
addition, the amount of HLA-DR-
expressing monocytes was significantly 
lower in ARF than nonARF patients on 
days 2 and 3 (Table 12). The ability to 
predict ARF by ROC analysis was from 
poor to moderate for the studied 
interleukins and monocyte HLA-DR 
expression (day 1 AUCs: IL-6: 0.641, Il-
8: 0.771, IL-10: 0.647, and HLA-DR 
expression: 0.420).  
 
RIFLE  Bellomo  
No ARF 316 / 658 
(48%) 
No ARF 520 / 658
(79%) 
Risk  168 / 658 
(26%) 
ARI 85 / 658
(13%) 
Injury  100 / 658 
(15%) 
ARFS 16 / 658
(2%) 
Failure  74 / 658 
(11%) 
SARFS 37 / 658
(6%) 
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Table 12. Plasma cytokine levels and monocyte HLA-DR expression in patients with (ARF) 
 and without (nonARF) acute renal failure in Study II. 




IL-6 (pg/mL) Day 1 614 (331-2000) 433 (124-1011) NS 
Day 2 365 (60-1000) 88   (31-601) <0.05 
Day 3 162 (31-1000) 51   (18-147) <0.05 
IL-8 (pg/mL) Day 1 91   (43-246) 28   (10-44) <0.001 
Day 2 86   (21-206) 21   (8-45) <0.001 
Day 3 87   (18-159) 21   (7-38) <0.001 
IL-10 (pg/mL) Day 1 12   (19-47) 7     (0-19) <0.05 
Day 2 7     (5-23) 0     (0-7) <0.001 
Day 3 5     (0-12) 0     (0-6) <0.05 
HLA-DR (%) Day 1 69   (51-87) 79   (62-92) NS 
Day 2 64   (43-80) 79   (60-91) <0.01 
Day 3 75   (44-83) 83   (75-93) <0.01 
ARF=acute renal failure, IL=interleukin, HLA-DR=Human histocompatibility leukocyte  
 antigen-DR, NS=not significant. 
 
5.3. Serum cystatin C in acute 
renal failure (III) 
 
In a heterogeneous ICU population, 
serum cystatin C concentrations 
measured throughout the ICU period 
ranged from 0.4 to 9.0 mg/l in patients 
who developed ARF at some point 
during their stay. In patients who did not 
develop ARF during their ICU period, 
serum cystatin C concentrations ranged 
from 0.3 to 3.9 mg/l. The development of 
serum cystatin C and plasma creatinine 
values is shown in Figure 3.  
Serum cystatin C concentrations 
correlated in a clinically significant 
manner with both plasma creatinine and 
plasma urea concentrations (Spearmans’s 
correlation coefficients for days 1-10 
were between 0.72 and 0.86, p<0.001) 
and inversely with the GFR estimated by 
the MDRD formula (Spearman’s 
correlation coefficients for days 1-10 
between -0.74 and -0.87). The correlation 
between the estimated GFR and serum 
cystatin C concentration on day one is 
shown in Figure 4. Based on the figure, a 
cut-off value of 1.5 mg/L for serum 
cystatin C was estimated, as values above 
this threshold were clearly associated 
with a decrease in GFR to less than 50 
mL/min/1.73m2. On the other hand, a 
normal serum cystatin C concentration 
did not sort out all patients with 
decreased GFR.  
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Figure 3. Development of serum cystatin C and plasma creatinine concentrations in patients 
 with and without ARF on days 1-10 in Study III. 
Figure 4. Simultaneous values of estimated (MDRD) glomerular filtration rate (GFR) and 
 serum cystatin C in patients on days 1-10 in Study III. 
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In 29 patients, plasma creatinine 
concentration was normal on admission, 
rising later to an abnormal level. The 
abnormal level was reached on day 3 
(median, range 2-11 days). In these 29 
patients, serum cystatin C also exceeded 
the reference range within a median of 3 
(range 1-6) days. The time interval for 
the creatinine increase was similar to that 
of the cystatin C increase (p=0.40, Mann-
Whitney U-test). Plasma creatinine 
remained normal throughout the study 
period in 80 patients, 28 (35%) of whom 
showed increased serum cystatin C. In 
these patients, the median for the highest 
serum cystatin C concentration was 1.29 
(interquartile range 1.15-1.65) mg/L. 
Serum cystatin C remained normal 
throughout the study period in 58 
patients, 7 (12%) of whom had increased 
plasma creatinine. In these patients, the 
median for the highest plasma creatinine 
concentration was 98 (interquartile range 
96-102) µmol/L. ROC analysis showed 
excellent predictive power in the 
prediction of ARF for days 1-3 serum 
cystatin C (AUCs 0.885, 0.893, and 
0.901, respectively). 
Treatment with corticosteroids 
increased serum cystatin C 
concentrations in nonARF patients. 
However, in ARF patients, a similar 
effect was not found. In nonARF 
patients, the medians for cystatin C 
concentrations in the first three days 
were 0.92, 1.07, and 1.15 (treated with 
corticosteroids) vs. 0.78, 0.85, and 0.92 
(no corticosteroids) (p=NS). In ARF 
patients, the respective figures were 2.50, 
2.60, and 2.51 vs. 2.75, 2.32, and 3.02 
(p=NS).  
5.4. Impact of 
hemodiafiltration vs. forced 
alkaline diuresis on plasma 
myoglobin levels in 
rhabdomyolysis (IV) 
The percentual elimination of myoglobin 
from the circulation during HDF was 
significantly greater than during FAD 
(p<0.05). When absolute plasma con-
centrations were compared, the differ-
rence in the elimination of myoglobin 
was not statistically significant, although 
a trend towards faster myoglobin eli-
mination during HDF was present. Table 
13 shows the elimination of myoglobin 
in percentual values and in absolute plas-
ma concentrations, and the AUCs for 
plasma myoglobin concentrations during 
HDF vs.FAD. 
ANOVA revealed no significant dif-
ferrences in plasma myoglobin concen-
tration over time between the treatment 
arms. Also, no significant carry-over 
effect was present. Complete case 
analysis yielded a mean difference in 
myoglobin clearances of 6085 (95% CI 
343-11828, median 4040, and inter-
quartile range -1257-11065) µg/l in four 
hours during HDF vs. FAD. The mean 
total amount of filtrated myoglobin at the 
end of HDF was 58.4 (95% CI 21.9-94.9, 
median 27.9, and interquartile range 
19.5-87.4) mg. Mean creatinine clearance 
in group A was 0.30 (median 0.04, 95% 
CI -0.39-0.99, interquartile range 0.01-
0.45) mL/s/1.73m2, and in group B 0.69 
(median 0.41, 95% CI 0.07-1.31, inter-
quartile range 0.17-1.20) mL/s/1.73m2.
No significant difference was found 
between the groups. 
Total urine output during the whole 
eight-hour study period was significantly 
lower in the group A than in group B; by  
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Table 13. Decrease in plasma myoglobin concentration (P-Myogl) and areas under curve 
 (AUC) during hemodiafiltration (HDF) and forced alkaline diuresis (FAD) in 
 Study IV in patients with rhabdomyolysis. The results of intention-to-treat (ITT, 
 n=16) and complete case analysis (n=14) are shown as mean (95% confidence 
 intervals).  
 ITT, using group 
average  
























AUC for HDF (µg/L/4h) 52 642  (24 854-80 430) 
54 456   
(26 211-82 700) 
51 997  
(22 141-81 853) 
AUC for FAD (µg/L/4h) 52 086  (23 689-80 484) 
57 469  
(28 421-86 518) 
53 123  
(20 134-86 111) 
*p<0.05. 
 
complete case analysis, medians 93 mL 
vs. 733 mL (interquartile ranges 51-484 
mL and 273-2181 mL), respectively 
(p=0.03). Mean urine output during HDF 
was also lower than during FAD 237 mL 
vs. 1664 mL, (medians 160 mL and 203 
mL, 95% CIs 9-465 mL and 398-2931 
mL, interquartile ranges 36-258 mL and 
29-564 mL), but the difference was not 
significant. Mean urine pH of the study 
population during the four hours of FAD 
was 6.2 (median 6.0, 95% CI 5.8-6.5, 
interquartile range 5.9-6.3). It was the 
same in both groups.  
 
5.5. Mortality in acute renal 
failure (I-III, V) 
Short-term mortality (I-III) 
According to the results of Studies I and 
III, the hospital mortality rate for ARF 
(defined as RIFLE stage “Failure”) in a 
heterogeneous critically ill patient 
population was 34% (43/128 patients): 
17/74 patients (23%) in Study I and 
26/54 patients (48%) in Study III. The 
28-day mortality rate in ARF patients 
with SIRS/sepsis determined in Study II 
was 8/36 patients (22%). Taken together, 
the overall short-term mortality rate in 
ICU patients with ARF was 31% (51/164 
patients). In patients without ARF the 
short-term mortality rate was 13% 
(101/808 patients): 59/584 patients 
(10%) in Study I, 12/67 patients (18%) in 
Study II, and 28/145 patients (28/148 
treatment episodes) (19%) in Study III. 
The difference in short-term mortality 
rates between patients with and without 
ARF was significant by the Mann-
Whitney U-test (p<0.001). Hospital mor-
tality differed significantly in the differ-
rent stages of ARF by the Χ2-test in the 
Study I (p ≤0.05, Figure 5).
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Figure 5. Hospital mortality in Study I stratified according to the separate stages of ARF. 
 ARF= acute renal failure, ARI= acute renal injury, ARFS= acute renal failure 
 syndrome,SARFS= severe acute renal failure syndrome.  p<0.05 is marked * and 
 p<0.001 is marked **. 
 
Survival of patients over time is 
presented in Figure 6. Sensitivities, 
specificities, and likelihood ratios for 
death are presented in Figure 7. 
Multiplying overall hospital mortality 
rate with the likelihood ratios resulted in 
total likelihoods for death of 17%, 22%, 
and 26% for the RIFLE stages of Risk, 
Injury, and Failure, respectively, and 
21%, 31%, and 36% for the Bellomo 
stages ARI, ARF, and SARFS, 
respectively.  
 
Long-term mortality (V) 
In the Study V, the long-term mortality 
of ARF patients needing RRT during 
hospitalization was 41% (277/681) in 28 
days, 57% (387/681) in one year, and 
70% (120/172) in 5 years (Figure 8). 
Nonsurvivors were older than survivors: 
64 (interquartile range 53-73) years vs. 
55 (interquartile range 43-67) years 
(p<0.001). The one-year mortality rate 
differed significantly between the 
patients treated in the ICU (57%, 
317/553) and patients treated in the 
hospital wards (47%, 70/150) (p<0.05). 
No significant differences were present 
in the one-year mortality rate of patients 
treated in different years (1998-2002) 
(p=NS). 
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Figure 6. Survival of patients over time stratified according to the separate stages of acute 
 renal failure (ARF) in Study I. ARI= acute renal injury, ARFS= acute renal failure 
 syndrome, SARFS= severe acute renal failure syndrome. 
 
Figure 7. Sensitivities, specificities, and likelihood ratios (LRs) for death at each stage of acute 
renal failure (ARF) according to the RIFLE and Bellomo classifications (Study I). 
RIFLE= risk, injury, failure, loss of renal function, end-stage renal disease, ARI= 
acute renal injury, ARFS= acute renal failure syndrome, SARFS= severe acute renal 
failure syndrome.
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Figure 8. Long-term survival of acute renal failure patients in Study V. 
 
5.6. Prediction of mortality in 
acute renal failure (I-III) 
Scoring methods for severity of 
illness (I) 
1. ARF-SPECIFIC SCORING METHODS (I) 
Logistic regression analysis revealed 
that the maximum RIFLE score for the 
first three days was an independent 
predictor of hospital mortality. The ROC 
analysis showed only moderate power in 
discriminating hospital mortality for both 
ARF-specific scoring methods studied, 
AUCs varying from 0.581 to 0.653 
(Table 14). Secondary analysis with all 
683 treatment episodes revealed no 
significant differences in the results.  
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Table 14. Predictive power for hospital mortality of the ARF-specific severity-of-illness 
 scoring methods in Study I. 
Scoring method AUC 95% CI 
RIFLE classification:  day one 0.630 0.558 - 0.701
max. score for the first 3 days 0.653 0.588 - 0.719 
Bellomo classification: day one 0.581 0.497 - 0.664
max. score for the first 3 days 0.587 0.514 - 0.660
ARF= acute renal failure, RIFLE= risk, injury, failure, loss of renal function, end-stage renal 
 disease, AUC= area under curve. 
 
2. GENERAL SEVERITY-OF-ILLNESS 
SCORING METHODS (I-III) 
The ability of general severity-of-illness 
scoring methods to independently predict 
short-term mortality was tested in Studies 
I-III using scores on the day of admission 
to ICU. The day 1 SOFA score appeared 
as an independent predictor of hospital 
mortality in Studies I and III, but not as 
an independent predictor of 28-day 
mortality in Study II. The APACHE II 
score was as an independent predictor of 
28-day mortality in Study II and hospital 
mortality in Study III, but neither in 
Study I. However, in a secondary 
analysis with all 683 treatment episodes, 
the results changed and admission 
APACHE II score was as an independent 
predictor of hospital mortality in Study I 
as well. When the three study 
populations were combined to form one 
large study population, both APACHE II 
and SOFA scores for day 1 appeared to 
predict short-term (hospital or 28-day) 
mortality independently. 
In Study I, also the discriminative 
powers for hospital mortality of the 
admission-day APACHE II and SOFA 
scores were calculated. The AUCs were 
0.703 (95% CIs 0.637 - 0.769) and 0.725, 
(95% CI 0.657 - 0.794), respectively. In 
Studies II and III, the APACHE II and 
SOFA scores were not included in the 
original ROC analysis. However, we 
determined the AUCs afterwards. For the 
APACHE II score, the AUCs were 0.795 
(95% CI 0.590-0.779) and 0.681 (95% CI 
0.601-0.761), respectively. For SOFA 
score the AUCs were 0.741 and 0.648 
(95% CIs 0.630-0.853 and 0.557-0.740, 
respectively). Furthermore, total AUCs 
for the general severity-of-illness scoring 
methods for all three studies was deter-
mined. For admission-day APACHE II 
score, the total AUC was 0.687 (95% CI 
0.641-0.732), and for admission-day 
SOFA score 0.722 (95% CI 0.675-
0.769). 
 
Laboratory tests (II, III) 
1. SERUM CONCENTRATIONS OF 
INTERLEUKINS 6, 8, AND 10 (II) 
Forward stepwise multiple logistic 
regression analysis in Study II revealed 
that only the admission IL-8 value was 
independently associated with 28-day 
mortality. The association was lost, 
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however, if APACHE II was included in 
the analysis. The ability of the 
interleukins to predict mortality among 
ARF patients was evaluated using ROC 
analysis. The analysis showed moderate 
discriminative power in prediction of 
survival only for day 2 plasma levels of 
IL-6 and IL-10 (AUCs 0.703 and 0.749, 
respectively). 
 
2. MONOCYTE HLA-DR EXPRESSION (II) 
In forward stepwise multiple logistic 
regression analysis, HLA-DR expression 
was found not to be independently 
associated with 28-day mortality. 
Furthermore, it showed poor predictive 
power for mortality in ARF patients in 
ROC analysis: AUCs for monocyte 
HLA-DR expression were 0.630 
(standard error (SE) 0.112) on day 1, 
0.602 (SE 0.321) on day 2, and 0.644 
(SE 0.150) on day 3.  
 
3. SERUM CYSTATIN C CONCENTRATION 
(III) 
Regarding hospital mortality in patients 
with ARF, ROC analysis showed only 
weak predictive power for serum cystatin 
C in Study III. The AUC for day 1 serum 
cystatin C was 0.624. Forward stepwise 
multiple logistic regression analysis 
revealed that serum cystatin C was not an 
independent predictor of hospital 
mortality. 
 
4. PLASMA CREATININE CONCENTRATION 
(III) 
Only weak predictive power for plasma 
creatinine concentration regarding 
hospital mortality was found in Study III. 
The AUC for plasma creatinine 
concentration was 0.598. However, 
forward stepwise multiple logistic 
regression analysis revealed that 
admission plasma creatinine 
concentration was an independent 
predictor of hospital mortality (p=0.01) 
in this study.  
5.7. Quality of life after acute 
renal failure (V) 
Health-related quality of life (V) 
In Study V, of the 229 survivors in 2003 
whose address was confirmed by the 
Central Population Registry, 153 (67%) 
returned the EuroQol five dimensions 
(EQ-5D) questionnaire for health-related 
quality of life including the visual analog 
scale (VAS) for self-perceived health. 
The EQ-5D index score of the study 
population was significantly lower than 
the EQ-5D index score of the age- and 
gender-matched general population 
(median 0.68, interquartile range 0.53-
0.85) vs. (median 0.86, interquartile 
range 0.83-0.88), p<0.001. However, the 
VAS score was slightly higher in the 
study group than in the age- and gender-
matched general population (70.0 (54.8-
84.0) vs. 69.5 (67.8-78.1), p<0.05). 
Patients in the three age groups (≤50
years, 51-65 years, >65 years) did not 
differ from one another regarding EQ-5D 
index score, VAS score, gender, length 
of treatment or follow-up, stay in ICU, or 
Z-score. However, the EQ-5D index 
score and the Z-score for the age groups 
differed significantly from those of the 
age- and gender-matched general 
population (Table 15). 
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Table 15. Health-related quality of life (HRQoL) of the study population (Study V) measured 
 by the EuroQol (EQ-5D) index and the visual analogue scale (VAS) and  compared 
 with the age- and gender-matched (Finnish) general population by Z-scores. The 
 EQ-5D and VAS scores are presented as medians (interquartile ranges), and the Z-
 scores as means. 
 
EQ-5D index score VAS score 
≤50 years (n=42) 
General population (Z-score) 
0.69 (0.51-0.85)** 
0.93            (5.1**) 
81.5 (56.3-90.0)* 
84.4             (3.1) 
51-65 years (n=56)  
 General population (Z-score) 
0.69 (0.52-0.84)** 
0.86          (15.0**) 
68.5 (51.0-80.0) 
69.5             (1.4) 
>65 years (n=55) 
 General population (Z-score) 
0.65 (0.53-0.80)** 
0.81            (3.5**) 
70.0 (53.8-79.3) 
65.7             (0.3) 
Whole group (n=153) 
 General population (Z-score) 
0.68 (0.53-0.85)** 
0.86            (3.4**) 
70.0 (54.8-84.0)* 
69.5             (0.7)     
*p<0.05, **p<0.0001 
 
Age, follow-up time, treatment modality, 
length of RRT, number of RRT 
treatments, APACHE II score, SOFA 
score, and EQ-5D score of the age- and 
gender-matched general population did 
not correlate with the EQ-5D index score 
(correlation coefficients –0.06, -0.00, 
0.09, -0.08, -0.06, -0.02, -0.01, and 0.05, 
respectively, NS). The respondents’ 
detailed answers to the five dimensions 
of the EQ-5D are presented in Table 16.  
 
Quality-adjusted life-years and 
costs of treatment (V) 
Quality-adjusted survival was investi-
gated in Study V, where 15 quality-
adjusted life-years per 100 patients was 
found for ARF patients in the first year. 
Including the entire survival time in the 
analysis did not increase the number of 
quality-adjusted life-years. The total 
costs of hospital treatment were 28 000 
(22 000-37 000) € per patient, 222 000 
(41 000-1 610 000) € per quality-
adjusted life-year for the first year and 
222 000 (14 000-1 610 000) € per 
quality-adjusted life-year for the entire 
survival period.  At the same time the 
cost for RRT per quality-adjusted life-
year was 25 000 (2000–191 000) €. 
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Table 16. EuroQol five dimensions (EQ-5D) health questionnaire and distribution of 
 responses (n=153) in Study V. 
 Number of patients (%) 
Mobility 
I have no problems in walking about.      
I have some problems in walking about. 






I have no problems with self-care.      
I have some problems washing or dressing myself.     




Usual activities (e.g. work, study, housework, family, or 
leisure activities) 
I have no problems with performing my usual activities. 
I have some problems with performing my usual activities. 






I have no pain or discomfort. 
I have moderate pain or discomfort. 
I have extreme pain or discomfort. 
 
68 (44) 
 75 (49) 
 10 (7) 
Anxiety/Depression 
I am not anxious or depressed. 
I am moderately anxious or depressed. 








6.1. Incidence of acute renal 
failure (I-IV) 
The incidence of ARF in these studies 
varied from 11% to 37.5%. This is 
slightly higher than in previous studies 
on ARF, which have reported figures 
between 5% and 25% in patients 
admitted to ICUs, depending on the 
patient population and the severity of 
illness required to meet the definition of 
ARF (Groeneveld et al. 1991; Brivet et 
al. 1996; de Mendonca et al. 2000; 
Metnitz et al. 2002; Uchino et al. 2005). 
Moreover, the incidence of ARF in a 
heterogeneous ICU patient population 
varied considerably; also among studies 
where similar definitions of ARF were 
used (I and III). This might be explained 
by the much larger proportion of septic 
patients in Study III (20% vs. 7%), as 
sepsis is known to have the highest 
occurrence rate for ARF among critically 
ill patients, up to 50% (Brivet et al. 1996; 
Uchino et al. 2005). Confirmation of the 
high incidence of ARF in septic patients 
was provided by Study II, where the 
occurrence rate of ARF in patients with 
SIRS/sepsis was 35%. However, in this 
study the degree of illness required for 
the diagnosis of ARF was less severe 
than in Studies I and III. Contradicting 
previous reports, the highest incidence 
for ARF (37.5%) was found in patients 
with severe rhabdomyolysis. Study IV 
had very strict inclusion criteria, 
resulting in a highly selected patient 
population and the sample size was not 
designed to detect differences in the 
incidence of ARF.  
In Study I, the RIFLE criteria for 
ARF were fulfilled in approximately 
twice as many patients as the Bellomo 
criteria. The distribution of patients 
according to the RIFLE criteria was 
inconsistant with an earlier study on the 
subject (Risk: 26% vs. 8%, Injury: 15% 
vs. 22%, Failure: 11% vs. 22%, and Loss 
+ End-Stage Renal Disease: 0% vs. 9%) 
(Bell et al. 2005). However, the basic 
design of the studies differed, as the 
RIFLE definition was used in different 
ways. The distribution of patients in the 
separate stages of ARF according to the 
Bellomo classification was roughly 
similar to the distribution reported earlier 
(ARI: 13% vs. 18%, ARFS: 2% vs. 6%, 
and SARFS: 6% vs. 4%)  (Ostermann et 
al. 2005). The small number of patients 
in the ARFS stage in our study reflects 
the tendency to start RRT early in the 
course of ARF. As a consequence, most 
patients who would otherwise be 
classified as having ARFS are classified 
as having SARFS. We found the 
distributions of the RIFLE and Bellomo 
classifications for ARF to correspond but 
only weakly, in Kendall’s W-test.  
 
6.2. Monocyte human 
histocompatibility leukocyte 
antigen-DR (HLA-DR) 
expression and cytokine 
plasma levels in 
pathogenesis of acute renal 
failure (II) 
The results of the Study II demonstrated 
that monocyte HLA-DR expression and 
plasma levels of IL-6, IL-8, and IL-10 
differ significantly between ARF and 
65
nonARF patients. Monocyte HLA-DR 
expression was lower and plasma 
concentrations of IL-6, IL-8, and IL-10 
higher in ARF than in nonARF patients 
on days 2 and 3. On day 1, a significant 
difference was found in IL-8 and IL-10 
plasma concentrations.  
The expression of HLA-DR on 
monocytes was significantly lower in 
ARF patients than in nonARF patients on 
days 2 and 3. Generally, low HLA-DR 
expression on monocytes is considered 
an anti-inflammatory response, as 
monocyte HLA-DR expression is needed 
for antigen presentation for T-cells 
(Nunez et al. 1987; Cheadle 1993). On 
the other hand, HLA-DR expression on 
monocytes is upregulated by pro-
inflammatory cytokines, predominantly 
interferon γ (Donnelly et al. 1990).  
Previous results on monocyte HLA-DR 
expression in ARF are sparse. One study 
reported increased histocompatibility 
class II protein expression in the 
interstitium, in collecting tubules, and on 
periglomerular cells in a rat model of 
ischemia/reperfusion injury in the kidney 
(Takada et al. 1997). Another study 
described lower monocyte HLA-DR 
expression in sepsis patients than in a 
heterogeneous ICU population (Lin et al. 
1994). However, these results do not 
contradict the results of the Study II, as 
the earlier study did not include ARF 
patients as a subgroup. Despite all 
patients in the Study II being diagnosed 
with SIRS/sepsis and their monocyte 
HLA-DR expression as a group being 
decreased, the patients with ARF had an 
even lower monocyte HLA-DR 
expression.  
 ARF patients had significantly 
higher IL-6, IL-8, and IL-10 concen-
trations than nonARF patients, except for 
IL-6 concentration on day 1. This is in 
accord with evidence from a previous 
study, where increased plasma levels of 
IL-1β, IL-6, IL-8, IL-10, and TNF-α
were observed in ARF patients compared 
with healthy subjects or patients with 
end-stage renal disease (Simmons et al. 
2004).  Furthermore, in rat studies an 
increase in IL-6 expression and IL-6 
gene upregulation after ischemic injury 
have been found (Takada et al. 1997; 
Lemay et al. 2000; Kielar et al. 2005). 
Other studies on interleukin levels in 
ARF have measured urine levels of IL-6 
and IL-8 (Dohi et al. 1991; Smith et al. 
2000). One of these studies demonstrated 
an association between high levels of IL-
6 in urine and progression of IgA 
nephropathy (Dohi et al. 1991). The 
other found increases in IL-6 and IL-8 in 
urine during renal transplant rejection 
(Smith et al. 2000). Support for the 
central role of cytokines in the 
pathogenesis of ARF emerged in a study 
where T-cell-deficient mice developed a 
less severe kidney dysfunction than wild-
type mice after ischemic injury (Burne et 
al. 2001).   
 
6.3. Cystatin C in diagnosing 
acute renal failure (III) 
Abnormal values of serum cystatin C and 
plasma creatinine seemed to appear 
equally quickly in ARF. Serum cystatin 
C concentrations correlated with plasma 
creatinine and plasma urea 
concentrations and showed excellent 
predictive value for ARF in ROC 
analysis. One recent study in critically ill 
patients reported cystatin C to increase 
almost two days earlier than creatinine in 
ARF patients (Herget-Rosenthal et al. 
2004). This discrepancy in conclusions 
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may be explained by differences in 
patient selection. Subjects in Study III 
were consecutive ICU patients without 
exclusions, whereas in the study by 
Herget-Rosenthal et al. several 
exclusions were made. Their study only 
included patients with several risk factors 
for developing ARF. Furthermore, all 
patients with ARF at admission or at risk 
for quickly developing severe ARF were 
excluded. Hence, their patients 
represented a subgroup of ICU patients 
that was likely to develop ARF slowly. 
This design was likely better in detecting 
small changes in GFR and in testing the 
sensitivity of markers of kidney function. 
Study III, by contrast, was aimed at 
detecting a clinically significant result for 
the average ICU patient. We cannot 
therefore rule out a more sensitive nature 
of cystatin C in detecting ARF in patient 
subgroups.  
In Study III, the increase in serum 
cystatin C concentration occurred as 
quickly as the increase in plasma 
creatinine concentration. The results are 
in disagreement with two studies in 
critically ill patients, which determined 
the ability of serum cystatin C to detect 
small changes in GFR, measured by 
creatinine clearance or by the Cockcroft-
Gault formula (Delanaye et al. 2004; 
Villa et al. 2005). In both of these 
studies, the GFR limit for ARF was set at 
<80 mL/min/1.73m2. One of these 
studies reported that the ability to detect 
ARF was better with serum cystatin C 
than with plasma creatinine by ROC 
analysis (Villa et al. 2005). The other 
failed to show any difference for serum 
cystatin C and plasma creatinine in the 
ROC analysis, but noted that abnormal 
values of serum cystatin C were seen 
significantly more often than abnormal 
values of plasma creatinine in patients 
with diminished GFR (Delanaye et al. 
2004). One recent study, by contrast, is 
in agreement with the results of the Study 
III (Mazul-Sunko et al. 2004). In this 
study serum cystatin C did not associate 
with ARF in critically ill patients with 
sepsis. 
Treatment with corticosteroids had no 
effect on serum cystatin C concentrations 
in ARF patients. However, in nonARF 
patients, increased serum cystatin C 
concentrations were found during 
corticosteroid treatment. Previous results 
on the subject are contradictory. One 
study demonstrated a dose-dependent 
increase in cystatin C concentrations 
during corticosteroid treatment (Risch et 
al. 2001). However, the dose of 
corticosteroid treatment in this study was 
larger than in ours, and the patients also 
received treatment with cyclosporine A 
and azathioprine. Two studies in children 
present contrary results, where 
corticosteroid treatment had no effect on 
cystatin C concentrations (Bökenkamp et 
al. 1998; Foster et al. 2006).  
 
6.4. Prevention and treatment 
of acute renal failure in 
rhabdomyolysis (IV) 
The results of the Study IV demonstrated 
that clearing myoglobin from plasma is 
possible using HDF. Approximately 60 
mg of myoglobin was found in the 
ultrafiltrate after four hours of HDF. 
Myoglobin clearance was about 50 
mL/min, and the sieving coefficient for 
myoglobin was 0.31. The results are in 
accordance with evidence from previous 
studies on myoglobin clearance during 
continuous hemofiltration (Nicolau et al. 
1996; Amyot et al. 1999). In an animal 
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model of rhabdomyolysis-induced ARF 
treated with continuous arteriovenous 
hemofiltration (CAVH), the amount of 
myoglobin filtrated in six hours was 
around 400 mg. In a case report of a 
patient with a very high plasma 
myoglobin concentration, the amount of 
myoglobin removed in 16 h of 
continuous venovenous hemofiltration 
(CVVH) was around 700 mg (Amyot et 
al. 1999). Continuous venovenous 
hemodiafiltration (CVVHDF), on the 
other hand, has not been shown to 
increase plasma myoglobin clearance 
(Mikkelsen et al. 2005). One explanation 
might be that CVVHDF was started 
because of ARF and was not aimed 
solely at clearing myoglobin (Mikkelsen 
et al. 2005).  
The reduction of plasma myoglobin 
during four hours of forced alkaline 
diuresis in Study IV was around 15% of 
the baseline concentration. This is 
consistent with the few previous studies 
available, where the daily disappearing 
rates of myoglobin in rhabdomyolysis 
patients without ARF have been reported 
as 43% and 62% (Wakabayashi et al. 
1994; Mikkelsen et al. 2005). In the 
present study, the myoglobin elimination 
rate without urine alkalization was not 
measured, which makes calculation of 
the effect of urine alkalization on 
myoglobin baseline elimination rate 
impossible. One study has demonstrated 
that myoglobin clearance via kidneys is 
low, only 3 mL/min (Lappalainen et al. 
2002). This suggests that the increase in 
myoglobin clearance by urine 
alkalization is small. Thus, the decrease 
in myoglobin concentrations observed in 
our study probably reflects the baseline 
metabolic rate of myoglobin. 
The results of the Study IV indicate 
that compared to the conventional 
treatment of rhabdomyolysis with FAD 
the elimination of myoglobin is faster 
when HDF is added to the treatment. In 
Study IV, the percentual decrease in 
myoglobin concentration was signi-
ficantly greater during HDF than during 
FAD alone. The mean additional removal 
of myoglobin with HDF was around 
6000 µg/L (95% CIs 300-12000 µg/L). 
 
6.5. Mortality in acute renal 
failure (I-III, V) 
Short-term mortality (I-III) 
The overall short-term mortality rate 
among critically ill patients with ARF 
was 30%, varying from 20% (Studies I-
II) to 48% (Study III). The short-term 
mortality rate was relatively low 
compared with the mortality rates 
presented in several other studies on 
ARF patients (Uchino et al. 2005; Ympa 
et al. 2005). Remarkably, the 28-day 
mortality rate in ARF patients with 
SIRS/sepsis was only 22%. This may be 
explained by the majority of ARF 
patients not having sepsis despite having 
SIRS. Only 22% of SIRS patients with 
ARF were actually diagnosed with 
sepsis. In patients without ARF, the 
overall hospital mortality rate of 13% 
was significantly lower than that in 
patients with ARF. 
In the Study I, hospital mortality 
increased as the severity of ARF 
increased (graded according to RIFLE 
and Bellomo scores). This is in 
accordance with previous results, where 
the severity of renal dysfunction has been 
found to correlate with mortality (Kellum 
et al. 2002; Abosaif et al. 2005; Bell et 
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al. 2005; Ostermann et al. 2005). 
Regarding hospital mortality, sensitivity 
was better with the RIFLE classification 
and specificity with the Bellomo 
classification. Both classifications 
showed good sensitivity for death in the 
least severe stage of ARF (either Risk or 
ARI) and good specificity for death in 
the most severe stage (either Failure or 
SARFS).  
The observed short-term mortality of 
ARF patients was comparable with or 
higher than the short-term mortality of 
other critically ill patients reported 
previously. Two large studies on ICU 
patients documented significantly lower 
hospital mortalities in heterogeneous 
ICU populations: 12% (Zimmerman et 
al. 1998) and 10% (Niskanen et al. 
1996). However, a recent meta-analysis 
reported higher hospital mortality rates in 
a heterogeneous ICU population: 
between 11% and 64% (Williams et al. 
2005). 
 
Long-term mortality (V) 
Based on the results of the Study V, 
the long-term mortality of ARF patients 
treated with RRT is high, although it 
slows down with time. After hospital 
discharge, an additional mortality of 20% 
occurred during the first year. An 
additional mortality of 10% of patients 
occurred over the next four years, 
resulting in a total 5-year mortality of 
70%. Outcome was independent of 
treatment year, increasing the reliability 
of the Kaplan-Meier estimates of survival 
for patients with different follow-up 
times. The results are in accord with 
those of several previous studies, which 
have all documented the mortality rate to 
be extremely high at the beginning of 
illness, but then to slow down (Gopal et 
al. 1997; Korkeila et al. 2000; Morgera et 
al. 2002; Bell et al. 2005; Luckraz et al. 
2005). One previous Finnish study 
documented mortality rates very similar 
to ours. In their study, the mortality of 
ARF patients was 55% at 6 months and 
65% at 5 years (Korkeila et al. 2000). 
Another recent study with 207 ARF 
patients treated with CRRT reported the 
mortality rate to be 55% already at 60 
days and the 6-month mortality rate was 
higher; 60% (Bell et al. 2005). In 
cardiopulmonary bypass patients 
requiring RRT for ARF postoperatively, 
the long-term mortality was fairly low; 1- 
and 5-year mortality rates were 47% and 
48%, respectively (Luckraz et al. 2005). 
A higher 6-month mortality rate of 73% 
has been reported in a study of 490 ARF 
patients treated with RRT  (Hamel et al. 
1997). 
Comparison of the long-term 
mortality of ARF patients with the 
mortality of other ICU patients reveals 
that mortality of the former ARF patients 
remains higher several years. A Finnish 
study has demonstrated the long-term 
mortality of heterogeneous ICU patients 
to be 36% at 1 year, 48% at 5 years, and 
51% at 6 years (Kaarlola et al. 2003). 
 
6.6. Prediction of hospital 
mortality in acute renal failure 
(I-III) 
Scoring methods for severity of 
illness (I) 
1. ARF-SPECIFIC SCORING METHODS (I) 
 The maximum RIFLE score for the 
first three days in the ICU was found to 
be an independent predictor of hospital 
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mortality in the Study I. Previous studies 
on the subject are few (Abosaif et al. 
2005; Ostermann et al. 2005). Recently, a 
single study proposed that the RIFLE 
score would improve the predictive 
ability of general severity-of-illness 
scores in ARF patients (Abosaif et al. 
2005). However, this study had several 
major limitations: the study population 
was selected, ICU mortality instead of 
hospital mortality was evaluated, and the 
statistical analysis was flawed due to 
inadequate ROC and logistic regression 
analyses. In Study I, the Bellomo 
classification did not predict hospital 
mortality independently. This contradicts 
one previous study on the subject, which 
found all three stages of the Bellomo 
classification to be independent 
predictors of hospital mortality 
(Ostermann et al. 2005). This difference 
in results might be explained by 
differences in study populations. In the 
study by Ostermann et al., nearly 20% of 
survivors and over 30% of nonsurvivors 
were reported to have an underlying 
chronic end-stage disease, and the 
mortality rates were higher, although the 
APACHE II scores did not differ.  
While the RIFLE classification was 
found to be an independent predictor of 
hospital mortality, its power in 
discriminating between survivors and 
nonsurvivors was only moderate, and the 
discriminative power of the Bellomo 
classification was similar. These findings 
are in line with the results of a recent 
large study that evaluated four ARF-
specific scoring methods and described 
their discriminative powers for mortality 
as moderate (Uchino et al. 2005). The 
difference between the RIFLE and 
Bellomo classifications, and the scores 
by Liano et al. (1993), Chertow et al. 
(1998), Mehta et al. (2002), and Paganini 
et al. (1996) is that the first two focus on 
scoring the severity of ARF, whereas the 
latter four score the general severity of 
illness in ARF patients. The results 
suggest that ARF-specific severity-of-
illness scoring methods in general tend 
not to perform ideally as predictors of 
mortality in heterogeneous ICU 
population. However, in Study I, the 
maximum RIFLE score for the first three 
days in the ICU proved to be an 
independent predictor of hospital 
mortality, indicating that the RIFLE 
score may be suitable for classification of 
ARF patients in clinical mortality 
studies. 
 
2. GENERAL SEVERITY-OF-ILLNESS 
SCORING METHODS (I-III) 
The two general severity-of-illness 
scores, the APACHE II score and the 
SOFA score, performed well as 
predictors of mortality in these studies. 
They were both found to be independent 
predictors of short-term mortality in this 
large heterogeneous ICU population 
(Studies I-III combined). This finding is 
in agreement with earlier studies, where 
APACHE II and SOFA score have 
predicted mortality in ARF patients with 
AUCs of 0.747-0.878 and 0.868, 
respectively (van Bommel et al. 1995; 
Brivet et al. 1996; Parker et al. 1998; de 
Mendonca et al. 2000; Chen et al. 2001). 
The discriminative power concerning 
short-term mortality for APACHE II and 
SOFA scores ranged from moderate to 
good in Studies I-III. Previous studies on 
the subject show divergence. In ARF 
patients and in a general ICU population, 
the discriminative power for mortality 
has been reported as excellent for the day 
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1 SOFA score (Janssens et al. 2000; 
Mehta et al. 2002), in a heterogeneous 
ICU population as good, with an AUC of 
0.776 (Pettilä et al. 2002), and in end-
stage renal disease patients in the ICU as 
moderate (Dara et al. 2004).  
 
Laboratory tests (II, III) 
1. SERUM CONCENTRATIONS OF 
INTERLEUKINS 6, 8, AND 10 (II) 
While Study II demonstrated signi-
ficantly higher IL-6 and IL-8 plasma 
concentrations in ARF patients than in 
nonARF patients, ROC analysis and 
logistic regression analysis failed to 
demonstrate any reliable benefit in 
outcome prediction for IL-6 and IL-8. 
ROC analysis showed moderate 
predictive power of only day 2 plasma 
levels of IL-6 and IL-10, and logistic 
regression analysis revealed that 
admission plasma IL-8 level, although 
not an independent variable, was second 
to APACHE II score in predicting 
mortality. Previous studies on this 
subject show great diversity. High IL-10 
plasma levels have been found in 
nonsurvivors among sepsis patients 
(Gogos et al. 2000) and among patients 
with meningococcal disease (Lehmann et 
al. 1995). One recent study with 98 ARF 
patients determined the plasma 
concentrations of exactly the same 
interleukins that were examined in Study 
II and observed significantly higher 
plasma levels of these interleukins in 
nonsurvivors than in survivors (Simmons 
et al. 2004). For each natural log unit rise 
in interleukin levels, they found the odds 
for death to rise accordingly, and 
concluded that the plasma levels of IL-6, 
IL-8, and IL-10 predict mortality in ARF 
patients. However, in logistic regression 
analysis with APACHE II score 
included, the only independent predictor 
of 28-day mortality was IL-6 (measured 
at the time of nephrology consultation). 
In one previous study reporting results 
similar to ours, IL-8 plasma levels, but 
not IL-6 plasma levels, were found to 
predict mortality  (Friedland et al. 1996). 
However, in neither of these studies was 
the ability of interleukins to predict 
mortality measured by ROC analysis, as 
has been recommended (Ruttimann 
1994); the studies merely reported an 
association between high interleukin 
levels and increased mortality.   
 
2. MONOCYTE HLA-DR EXPRESSION (II) 
The results of this study showed no 
discriminative power in predicting 
mortality for monocyte HLA-DR 
expression by ROC analysis. This is in 
contrast to earlier studies, where low 
monocyte surface expression of HLA-
DR has been associated with increased 
mortality in sepsis (Volk et al. 1996; 
Tschaikowsky et al. 2002). However, 
results have also documented no 
association between low monocyte HLA-
DR expression and mortality (Perry et al. 
2003). 
 
3. SERUM CYSTATIN C CONCENTRATION 
(III) 
In ROC analysis, the ability of serum 
cystatin C to discriminate between 
survivors and nonsurvivors in Study III 
was poor, although it was slightly better 
than that of plasma creatinine. However, 
forward stepwise multiple logistic 
regression analysis revealed that 
admission serum cystatin C 
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concentration was not an independent 
predictor for hospital mortality but that 
plasma creatinine concentration was. 
Serum cystatin C is therefore not 
clinically useful in predicting mortality 
of ARF patients. 
 
6.7. Quality of life after acute 
renal failure (V) 
Based on the results of Study V, the 
HRQoL of former ARF patients is lower 
than that of the age- and gender-matched 
general population. Their quality-
adjusted survival, measured by quality-
adjusted life-years (QALYs), is also 
inferior to other groups of critically ill 
patients (Angus et al. 2001). However, 
the patients are as satisfied with their 
health as the general population.  
 
Health-related quality of life (V) 
The answers of the former ARF patients 
to the EQ-5D questionnaire revealed that 
their HRQoL was significantly lower 
than that of the age- and gender-matched 
general population. The results are in 
accord with previous studies on the 
HRQoL after critical illness. A recent 
systematic review of 21 selected 
independent studies (out of a total of 
8894 studies) with altogether 7320 
patients concluded that the HRQoL of 
ICU survivors is lower than that of the 
general population (Dowdy et al. 2005). 
However, some earlier studies on ARF 
patients have reported a fairly good 
HRQoL after ARF (Gopal et al. 1997; 
Korkeila et al. 2000; Maynard et al. 
2003). One of these studies evaluated 62 
former ARF patients by the Nottingham 
Health Profile six months after discharge 
and described HRQoL after ARF to be 
good (Korkeila et al. 2000). In their 
study, most impairment was found in 
overall energy and the physical domain 
of HRQoL. Another study using the 
Nottingham Health Profile also reported 
impairments in mobility and energy in 35 
former ARF patients (Gopal et al. 1997).  
Furthermore, they reported physical pain, 
interrupted sleep, and depression to be 
common after a follow-up of 2.5 years. 
However, the validity of the results of 
both of these studies is compromised by 
the fact that the patients were not 
compared with the general population. 
Comparison of ARF patients’ HRQoL 
with that of the general population has 
been done earlier only in a small study of 
12 patients (Maynard et al. 2003). 
Contrary to our results, they found 
patients’ mental health to be comparable 
with and their physical health to be only 
slightly poorer than that of the general 
population, as measured by the Short 
Form Health Survey (SF-36) six months 
after discharge.  
Study V also evaluated patients’ 
perceived health by the VAS score. The 
results showed no clinically significant 
difference between former ARF patients 
and the age- and gender-matched general 
population. Evaluation of VAS scores in 
three separate age groups revealed a 
connection between age and perceived 
health. In older age groups, perceived 
health was increasingly similar between 
patients and their age- and gender-
matched peers. Whether this finding 
reflects diminishing general health in 
older people or younger patients’ greater 
expectations of health, or both, is 
unclear. The finding is consistant with a 
previous study on ICU patients, which 
had demonstrated improved perceived 
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health status following ICU treatment in 
the elderly (Konopad et al. 1995). 
The results of Study V are in 
agreement with previous findings (Gopal 
et al. 1997; Morgera et al. 2002; 
Maynard et al. 2003). The earliest of 
these studies reported that the majority of 
35 former ARF patients were satisfied 
with their health after a follow-up time of 
2.5 years (Gopal et al. 1997). Another 
study with 267 former ARF patients 
treated with CRRT described patients’ 
current health to be good or excellent for 
77% of respondents (Morgera et al. 
2002). The results of a small study of 12 
patients showed that the majority of 
patients rated their health as “good” or 
“fair” 6 months after discharge (Maynard 
et al. 2003). None of the patients in that 
study rated their health as “excellent”, 
and 25% rated it as “poor”. 
 
Costs of hospital treatment (V) 
Based on the results of Study V, the costs 
of hospital treatment per quality-adjusted 
life-years (QALYs) in ARF patients 
treated with RRT were high. This was 
due not only to the high cost of treatment 
but also to the poor quality-adjusted 
survival of these patients. Costs of RRT 
were 25 000 €, and total costs of hospital 
treatment were approximately 222 000 € 
/QALY. This was higher than the 
50 000-100 000 € limit usually conside-
red acceptable in the literature (Lee et al. 
1996; Hamel et al. 1997; Angus et al. 
2001, 2003). These results are in 
agreement with previous studies, which 
have demonstrated the total costs of 
treating patients with ARF to be high 
(Hamel et al. 1997; Korkeila et al. 2000; 
Sznajder et al. 2001). A recent Finnish 
study found the total costs of treating 
ARF to be around 80 000 € / 6-month 
survival (Korkeila et al. 2000). This 
study did not take into account the effect 
of quality-adjusted survival, which 
means that the total costs of treatment / 
QALY calculated from results is actually 
similar to ours. Another study with 490 
patients treated with RRT described the 
overall costs of treatments to be around 
130 000 $ (103 000 €) /QALY (Hamel et 
al. 1997). The costs per QALY in that 
study depended on the patients’ outcome 
category and ranged from 60 000 $ 
(48 000 €) to 270 000 $ (214 000 €) 
/QALY. The highest costs / QALY were 
noted in patients with the worst 
outcomes.  However, much lower costs 
per QALY have also been reported. One 
study found the total cost of hospital 
treatment of ARF patients to be around 
30 000 $ (24 000 €), but they also 
reported that ARF patients had the 
highest costs of treatment / QALY of all 
intensive care patients (Sznajder et al. 
2001). 
 
6.8. Limitations of the study 
Several limitations of these studies 
should be addressed. First, the optimal 
timing for evaluation of mortality 
associated with ARF is not clear. In 
studies I-III, hospital mortality was 
evaluated ignoring some of the later 
ARF-related mortality. In Study V, 
where the long-term mortality was 
evaluated after a median of 
approximately four years, the reported 
ARF-related mortality rate was probably 
overestimated.  
Second, the general severity-of-
illness scores have originally been 
validated using manual data collection. 
However, collection of data here was 
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mainly based on a computerized system. 
Computerized data collection has 
previously been shown to result in more 
frequent measurements, to increase the 
probability of detecting abnormal values, 
and to produce higher severity-of-illness 
scores (Suistomaa et al. 2000). In their 
study, where bias was reported, 
computerized data collection resulted in 
worse predictive power for mortality 
(Suistomaa et al. 2000). Hence, if any 
bias had occurred in our study, it would 
have been in favor of a less significant 
result.  
Third, in Studies II and III, the effect 
of continuous hemodiafiltration on the 
plasma cytokine levels and serum 
cystatin C levels could not be assessed. 
However, previous studies have failed to 
prove any clinically significant decrease 
in serum cytokine concentrations during 
continuous hemodiafiltration (Kellum et 
al. 1998; Suzuki et al. 2002). To date, the 
exact clearance rate of cystatin C during 
RRT is still unclear (Thysell et al. 1988; 
Kabanda et al. 1994; Tian et al. 1997; 
Campo et al. 2004). In Study III, a 
decrease in serum cystatin C 
concentrations was seen in ARF patients 
over time, whereas plasma creatinine 
concentration simultaneously increased. 
These results suggest that differences 
exist in RRT clearance rates of these 
markers or in their elimination half-lives.  
Fourth, no prior study data were 
available to be used as reference values 
in the power analysis in Study IV, which 
means that the values used in the power 
analysis were approximations derived 
from clinical experience. The appropriate 
sample size was calculated with 
approximated decreases in myoglobin 
concentration during the treatments. For 
HDF, the decrease was assumed to be 
around 12 000 µg/L, and for FAD around 
6000 µg/L, with a standard deviation for 
the difference of 6000 µg/L. However, 
the observed decreases in plasma 
myoglobin concentration were smaller 
than those anticipated in the power 
analysis. The mean plasma myoglobin 
decrease during HDF was around 10 000 
µg/L, and during FAD around 4000 
µg/L. Hence, the power analysis resulted 
in a sample size that was probably too 
small to reveal a statistically significant 
decrease in plasma myoglobin 
concentration during HDF. Thus, the 
maximal effect of HDF on myoglobin 
elimination that we could demonstrate 
was approximately 12 000 µg/L in four 
hours. 
Fifth, the optimal follow-up for 
measuring HRQoL after critical illness is 
still unclear. In a longitudinal  study with 
repeated HRQoL measurements, 
significant improvement in HRQoL 
occurred during the post-discharge 
period as late as several years after 
discharge (Pettilä et al. 2000; Kaarlola et 
al. 2003). On the other hand, a long 
period between hospital discharge and 
HRQoL measurement allows other 
significant life events to affect the 
HRQoL. Furthermore, information about 
patients’ pre-ICU HRQoL could not be 
obtained in Study V, and hence, no 
comparison between pre- and post-ICU 
data was made. This may have 
influenced the results since patients’ 
previous health state has been shown to 
affect the HRQoL after treatment (Ridley 
et al. 1997; Granja et al. 2002).  
Finally, in Study IV, treatment with 
FAD was not completely successful, as 
mean urine pH during treatment was 6.2 
and a statistically non-significant trend 
towards a higher median hourly diuresis 
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in group B than in group A was seen. 
However, previous studies have 
suggested that GFR does not affect 
myoglobin clearance rate (Lappalainen et 
al. 2002). Since urine pH and GFR have 
an effect on myoglobin toxicity in renal 
tubular cells, not on myoglobin clearance 
rate, the results were likely not 
confounded by the shortcomings of FAD. 
 
6.9. Clinical implications 
Several clinical implications are 
proposed based on the results of Studies 
I-V.  
Although mortality of ARF patients is 
high, the highest mortality rate occurs 
during hospitalization. With time, the 
mortality rate slows down. After a period 
of approximately six months to one year, 
the mortality rate reaches that of other 
ICU patients. These patients who survive 
are fairly content with their quality of life 
after ARF. Patients with the potential to 
survive thus seem to benefit from 
adequate treatment. Adequate treatment 
is, however, more expensive than the 
generally accepetd cost-effective figure 
of 50 000-100 000 € (Lee et al. 1996; 
Angus et al. 2001; Angus et al. 2003). 
Evidence suggests that to be effective the 
treatment should be started early and at a 
sufficient dose. This leads to the 
conclusion that in order to be able to 
provide adequate treatment to those able 
to benefit from it we need to be able to 
predict which patients will survive. Our 
ability to do this is, however, limited. 
Based on our results, APACHE II and 
SOFA scores are still the best predictive 
tools for outcome in critical care patients. 
To date, no ARF-specific scoring method 
with good predictive power for mortality 
exists. Whether the new consensus 
definition for ARF, the RIFLE definition, 
can be used in combination with the 
APACHE II score or the SOFA score to 
increase predictive power remains to be 
elucidated.  
As a marker of renal dysfunction, 
plasma creatinine concentration 
maintains its superior ranking. However, 
we found serum cystatin C to be as good 
as plasma creatinine in detecting ARF or 
predicting patient survival. It may even 
prove to be more sensitive than plasma 
creatinine in certain subgroups of 
patients. This especially applies to 
patients whose muscle mass is abnormal 
or in whom renal failure develops slowly. 
Finally, daily measurement of plasma 
cytokine concentrations or monocyte 
HLA-DR expression is unlikely to have a 
clinical application in critically ill 
patients with ARF.  
HDF can be used to clear myoglobin 
from the plasma. The clinical 
significance of this is, however, unclear. 
Even today, little is known about the 
effect FAD has on myoglobin 
elimination rate. The low success rate of 
FAD in this study is also often seen in 
clinical practice. On the other hand, HDF 
is more expensive and laborious than 
FAD. Therefore, treatment of rhabdo-
myolysis should be started with FAD. If 
urine alkalization is unsuccessful or the 
patient develops a need for RRT for ARF 
or for fluid overload, RRT with filtration 
techniques should be considered. 
 
6.10. Future perspectives 
As a whole, ARF has been studied 
extensively over the past decades. 
Abundant research on different 
prevention and treatment strategies, 
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possible renal function markers, and 
tools for outcome prediction exists. 
Despite many promising ideas, some 
basic questions remain unanswered.  
To date, the lack of a globally 
accepted definition for ARF complicates 
comparison of results between studies. 
As a consequence, drawing conclusions 
from systematic reviews and meta-
analyses on ARF is difficult, and 
guidelines for clinical practice are 
therefore somewhat uncertain. The 
RIFLE definition, which in this study 
seemed more promising than the 
Bellomo classification, is based on a 
consensus idea and has not been properly 
validated. In future, a large multinational 
study focusing on outcome is needed for 
the validation.  
An ideal marker of renal function 
needs to be produced at a constant rate in 
all age groups, should only be eliminated 
via the kidneys, and should neither be 
secreted nor reabsorbed in the tubules. 
Cystatin C appeared to be such a marker, 
but closer examination revealed that it 
does not perform as well in ARF as in 
chronic renal failure. Now other low 
molecular weight proteins, such as β-2-
microglobulin (Bianchi et al. 2001; 
Paskalev et al. 2001; Mojiminiyi et al. 
2003) and tumor-associated trypsin 
inhibitor (Tramonti et al. 2003), are 
being tested for their ability to function 
as markers of renal function. N-terminal 
prohormone of proatrial natriuretic 
peptide has been investigated as a 
potential marker of renal function, but 
studies of its accuracy in ARF are sparse 
(Mazul-Sunko et al. 2004). Another 
recently proposed marker of renal 
function is 2-(α mannopyranosyl)-L-
tryptophan (Takahira et al. 2001). 
Calcium-binding proteins have also been 
suggested as markers of tubular injury 
and recovery (Cheng et al. 2005). 
Furthermore, a multitude of potential 
new markers for renal function have 
recently been proposed in animal studies. 
However, further studies are needed in 
order to find an accurate marker for renal 
function in ARF. 
Different treatment methods for ARF 
have been examined widely. Several new 
potential therapies require further 
evaluation. As recently reviewed by 
Vesely (2006) the vessel dilator peptide, 
located within the atrial natriuretic 
peptide (ANP) prohormone, has shown 
promising results in humans. Prevention 
and treatment of radiocontrast media-
induced ARF have also been extensively 
investigated. However, no clear findings 
have emerged, and thus, more studies are 
needed. Even the efficiency of N-
acetylcysteine (NAC) in prevention of 
radiocontrast medium-induced ARF is 
still under debate, although several meta-
analyses already exist on the subject 
(Kshirsagar et al. 2004; Zagler et al. 
2006). More studies are also warranted 
on the effect of theophyllin in preventing 
ARF and mortality after exposure to 
radiocontrast media. In one study, 
isotonic sodium bicarbonate was reported 
as more effective in preventing contrast 
media-induced ARF than sodium 
chloride (Merten et al. 2004). In recent 
animal studies, several substances have 
shown promising results in reducing 
ischemic injury; these include ethyl 
pyruvate (Miyaji et al. 2003), erythro-
poietin (Patel et al. 2004), apotransferrin 
(de Vries et al. 2004), diallyl sulfide 
(Pedraza-Chaverri et al. 2003), choles-
terol-lowering drugs (Yokota et al. 
2003), endotelin receptor antagonists 
(Huang et al. 2002), and propionyl-L-
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carnitine (Mister et al. 2002). 
Interstingly, first animal studies on stem 
cell therapy in ARF have also been 
conducted (Kale et al. 2003; Morigi et al. 
2004).  
The number of ARF patients in one 
ICU is relatively low and obtaining large 
study populations requires combining 
patient material from several ICUs. 
However, in general, the number of 
multinational multicenter studies on ARF 
is low (Uchino et al. 2004; Uchino et al. 
2005; Uchino et al. 2005). Large studies 
on ARF, similar to those that exist on 
sepsis (Moreno et al. 1999; Angus et al. 
2004; Laterre et al. 2004) and acute 
myocardial infarction (Webb et al. 2001; 
Goldberg et al. 2004; Reed et al. 2005; 
Kauf et al. 2006), are needed.  
Studies on long-term outcome of 
ARF patients in particular, are sparse 
(Druml 2005; Radhakrishnan et al. 
2006), and this topic warrants more 
thorough coverage. Another area for 
elucidation is the cost-effectiveness of 
treating ARF (Hamel et al. 1997; 
Korkeila et al. 2000; Angus et al. 2001).  
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7. CONCLUSIONS 
Based on the results of these studies, the following conclusions can be drawn: 
 
1. According to two newly proposed scoring methods for ARF, the RIFLE and 
 the Bellomo classifications, increasing severity of renal dysfunction is 
 associated with increasing hospital mortality in critically ill patients.  
 
2. In critically ill patients with SIRS, monocyte HLA-DR expression is 
 significantly lower and plasma levels of IL-6, IL-8, and IL-10 significantly 
 higher in those with ARF than in those without ARF. Serum cystatin C 
 levels are significantly higher in critically ill patients with ARF than in 
 patients without ARF. Serum cystatin C seems to be as good as plasma 
 creatinine in detecting ARF in critical care patients. In acute renal 
 dysfunction, abnormal values of serum cystatin C and plasma creatinine 
 appear equally quickly. 
 
3. HDF can be used to clear myoglobin from plasma, which may hinder the 
 development of ARF in rhabdomyolysis.  
 
4. The outcome of patients with ARF is poor. Both short- and long-term 
 mortalities are high. The HRQoL of those who survive is lower than that of 
 the age- and gender-matched general population. However, these patients are 
 as satisfied with their health as the general population. 
 
5.  The ability of ARF-specific severity-of-illness scores (the RIFLE and 
 Bellomo scores) to predict hospital mortality is only moderate. 
 Monocyte HLA-DR expression, plasma concentrations of IL-6, IL-8, and IL-
 10, and serum cystatin C are not clinically useful in predicting mortality of 
 ARF patients.  
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